

**“A PROSPECTIVE STUDY TO COMPARE RESURFACING OF  
FACIAL ACNE SCARS IN ADULTS USING FRACTIONAL CO2  
LASER AS MONOTHERAPY VS FRACTIONAL CO2 LASER WITH  
TOPICAL VITAMIN C SERUM IN A TERTIARY HEALTH CARE  
CENTRE”**

**By**

**DR. CHANDRIKA NAYYAR, M.B.B.S.**



**DISSERTATION SUBMITTED TO  
SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND  
RESEARCH, TAMAKA, KOLAR, KARNATAKA,  
IN PARTIAL FULFILLMENT OF THE REQUIREMENT FOR THE  
DEGREE OF**

**DOCTOR OF MEDICINE  
(M.D.) IN  
DERMATOLOGY, VENEREOLOGY AND LEPROSY**

**Under the Guidance Of**

**DR. RAJASHEKAR. T. S. M.B.B.S., M.D.**

**Professor & Head Of Department**



**DEPARTMENT OF DERMATOLOGY, VENEREOLOGY AND  
LEPROSY SRI DEVARAJ URS MEDICAL COLLEGE, TAMAKA,  
KOLAR, KARNATAKA - 563101**

**APRIL-2022**

**SRI DEVRAJ URS ACADEMY OF HIGHER EDUCATION AND  
RESEARCH**

**DECLARATION BY THE CANDIDATE**

I hereby declare that this dissertation entitled “**A PROSPECTIVE STUDY TO COMPARE RESURFACING OF FACIAL ACNE SCARS IN ADULTS USING FRACTIONAL CO2 LASER AS MONOTHERAPY VS FRACTIONAL CO2 LASER WITH TOPICAL VITAMIN C SERUM IN A TERTIARY HEALTH CARE CENTRE**” is a bonafide and genuine research work carried out by me under the direct guidance of **DR. RAJASHEKAR. T.S**, Professor and Head of the Department of Dermatology, Venereology and Leprosy, Sri Devaraj Urs Medical College, Tamaka, Kolar, in partial fulfillment of the requirement for the degree of **M.D. IN DERMATOLOGY, VENEREOLOGY AND LEPROSY**.

Date:

Signature of candidate

Place: Kolar

**DR. CHANDRIKA NAYYAR**

**SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND  
RESEARCH, TAMAKA, KOLAR, KARNATAKA.**

**CERTIFICATE BY THE GUIDE**

This is to certify that the dissertation entitled “**A PROSPECTIVE STUDY TO COMPARE RESURFACING OF FACIAL ACNE SCARS IN ADULTS USING FRACTIONAL CO2 LASER AS MONOTHERAPY VS FRACTIONAL CO2 LASER WITH TOPICAL VITAMIN C SERUM IN A TERTIARY HEALTH CARE CENTRE**” is a bonafide and genuine research work done by **DR. CHANDRIKA NAYYAR** in partial fulfillment of the requirement for the degree of **M.D IN DERMATOLOGY, VENEREOLOGY AND LEPROSY** as per regulations of SRI DEVRAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH, KOLAR.

Date:

Place: Kolar

Signature of Guide

**DR. RAJASHEKAR.T. S MD.**

Professor and Head,  
Department Of Dermatology,  
Venereology and Leprosy,  
Sri Devaraj Urs Medical College.  
Tamaka, Kolar

**SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION**

**RESEARCH, TAMAKA, KOLAR, KARNATAKA.**

**ENDORSEMENT BY THE HOD, PRINCIPAL/HEAD OF THE**  
**INSTITUTION**

This is to certify that the dissertation entitled “**A PROSPECTIVE STUDY TO COMPARE RESURFACING OF FACIAL ACNE SCARS IN ADULTS USING FRACTIONAL CO2 LASER AS MONOTHERAPY VS FRACTIONAL CO2 LASER WITH TOPICAL VITAMIN C SERUM IN A TERTIARY HEALTH CARE CENTRE**” is a bonafide and genuine research work done by **DR. CHANDRIKA NAYYAR** under the guidance of **DR. RAJASHEKAR.T. S**, Professor and Head of Department of Dermatology, Venereology and Leprosy, Sri Devaraj Urs Medical College, Tamaka, Kolar.

Signature of HOD

**DR. RAJASHEKAR. T.S**

Professor & Head,

Department of

Dermatology

Sri DevarajUrs Medical

College,Tamaka, Kolar

Date:

Place: Kolar

Signature of Principal

**DR. P.N.SREERAMULU**

Principal,

Sri DevarajUrs Medical

College,Tamaka, Kolar

Date:

Place: Kolar

**SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION &  
RESEARCH, TAMAKA, KOLAR, KARNATAKA**

**ETHICAL COMMITTEE CERTIFICATE**

This is to certify that the ethics committee of Sri Devaraj Urs Medical College, Tamaka, Kolar has unanimously approved the dissertation work of **DR. CHANDRIKA NAYYAR**, a postgraduate student in the Department of Dermatology, Venereology and Leprosy of Sri Devaraj Urs Medical College entitled “**A PROSPECTIVE STUDY TO COMPARE RESURFACING OF FACIAL ACNE SCARS IN ADULTS USING FRACTIONAL CO<sub>2</sub> LASER AS MONOTHERAPY VS FRACTIONAL CO<sub>2</sub> LASER WITH TOPICAL VITAMIN C SERUM IN A TERTIARY HEALTH CARE CENTRE**” to be submitted to **SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION AND RESEARCH, TAMAKA KOLAR.**

Signature of Member Secretary

Ethical committee.

Date:

Place: Kolar



SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION & RESEARCH

SRI DEVARAJ URS MEDICAL COLLEGE  
Tamaka, Kolar

INSTITUTIONAL ETHICS COMMITTEE



No. SDUMC/KLR/IEC/138/2019-20 Date:11-10-2019

Members

1. Dr. D.E.Gangadhar Rao,  
(Chairman) Prof. & HOD of  
Zoology, Govt. Women's  
College, Kolar,
2. Dr. Sujatha.M.P.,  
(Member Secretary), Assoc.  
Prof. of Anesthesia, SDUMC,
3. Dr. C.S.Babu Rajendra Prasad,  
Prof. of Pathology,  
SDUMC
4. Dr. Srinivasa Reddy.P.,  
Prof. & HoD of  
Forensic Medicine, SDUMC
5. Dr. Prasad.K.C.,  
Professor of ENT, SDUMC
6. Dr. Sumathi.M.E  
Prof. & HoD of Biochemistry,  
SDUMC.
7. Dr. Bhuvana.K.,  
Prof. & HoD of Pharmacology,  
SDUMC
8. Dr. H.Mohan Kumar,  
Professor of Ophthalmology,  
SDUMC
9. Dr. Hariprasad, Assoc. Prof  
Department of Orthopedics,  
SDUMC
10. Dr. Pavan.K.,  
Asst. Prof of Surgery, SDUMC
11. Dr. Mahendra.M.,  
Asst. Prof. of Community  
Medicine, SDUMC

**PRIOR PERMISSION TO START OF STUDY**

The Institutional Ethics Committee of Sri Devaraj Urs Medical College, Tamaka, Kolar has examined and unanimously approved the Synopsis entitled "A Prospective Study to Compare Resurfacing of Facial Acne Scars in Adults using Fractional CO2 Laser as Monotherapy vs Fractional CO2 Laser with Topical Vitamin C Serum in a Tertiary Health Care Centre" being investigated by Dr.CHANDRIKA NAYYAR & Dr. Rajashekar T. S in the Department of Dermatology at Sri Devaraj Urs Medical College, Tamaka, Kolar. Permission is granted by the Ethics Committee to start the study.

*Sujatha.M.P.*  
Member Secretary

Member Secretary  
Institutional Ethics Committee  
Sri Devaraj Urs Medical College  
Tamaka, Kolar.

*[Signature]*  
Chairman

CHAIRMAN  
Institutional Ethics Committee  
Sri Devaraj Urs Medical College  
Tamaka, Kolar

**SRI DEVARAJ URS ACADEMY OF HIGHER EDUCATION**

**ANDRESEARCH, TAMAKA, KOLAR, KARNATAKA**

**COPY RIGHT**

**DECLARATION BY THE CANDIDATE**

I hereby declare that the Sri Devaraj Urs Academy of Higher Education and Research, Tamaka, Kolar, Karnataka shall have the rights to preserve, use and disseminate this dissertation/thesis in print or electronic format for academic /research purpose.

Date:

Place: Kolar

Signature of the candidate

**DR. CHANDRIKA NAYYAR**

**© Sri DevarajUrs Academy of Higher Education and Research, Tamaka,**

**Kolar, Karnataka.**





Drillbit Softtech India Pvt. Ltd


**Certificate of Plagiarism Check for Dissertation**


Author Name	Dr. CHANDRIKA NAYYAR
Course of Study	MD DERMATOLOGY, VENEREOLOGY & LEPROSY
Name of Guide	Dr.RAJASHEKAR T.S
Department	DERMATOLOGY, VENEREOLOGY & LEPROSY
Acceptable Maximum Limit	10%
Submitted By	librarian@sduu.ac.in
Paper Title	A PROSPECTIVE STUDY TO COMPARE RESURFACING OF FACIAL ACNE SCARS IN ADULTS USING FRACTIONAL CO2 LASER AS MONOTHERAPY VS FRACTIONAL CO2 LASER WITH TOPICAL VITAMIN C SERUM IN A TERTIARY HEALTH CARE CENTRE
Similarity	10%
Paper ID	422304
Submission Date	2021-12-02 17:39:00

  
Signature of Student

  
Head of the Department  
Professor & Head  
Dept. of Dermatology  
R.L. Jalappa Hospital & Research Centre  
Tumakota, Kolar  
Date:.....Time:.....

  
Signature of Major Advisor  
Dept. of Dermatology  
R.L. Jalappa Hospital & Research Centre  
Tumakota, Kolar  
Date:.....Time:.....

  
University Librarian  
University Library Learning Resource Centre  
Sri Devaraj Urs Academy of Higher  
Education & Research  
Tumakota, KOLAR-563103

  
Coordinator, UG & PG Program  
UG&PG Program, Faculty of Medicine,  
Sri Devaraj Urs Academy  
of Higher Education & Research,  
Tumakota, Kolar- 563103

This report has been generated by DrillBit Anti-Plagiarism



## ACKNOWLEDGEMENT

*One of the joys of completion of this dissertation is to look over the journey past and remember and thank all the people who have helped and supported me along this long but fulfilling road. First and foremost, I thank the Almighty for giving me the strength and ability to carry out this study.*

*I am deeply indebted and grateful to my guide, **Dr.Rajashekar. T.S.** Professor and Head, Department of Dermatology, Venereology and Leprosy, Sri DevarajUrs Medical College, for his able guidance, support, timely advice and constant encouragement throughout the period of the study.*

*I am very grateful to **Dr Hanumanthayya K**, Professor, Department of Dermatology, Venereology and Leprosy, Sri DevarajUrs Medical College, for his guidance and support.*

*I thank **Dr. Suresh Kumar K**, Assistant Professor, Department of Dermatology, Venereology and Leprosy, Sri DevarajUrs Medical College, for his advice and support during my post graduation.*

*I would also like to warmly extend my gratitude to **Dr.Uday Kumar S, Dr Amulya Y.S**, Senior Residents, Department of Dermatology, Venereology and Leprosy, Sri Devaraj Urs Medical College, for their constant encouragement.*

*No words can express the gratitude I feel towards my beloved parents, **Mr. Neetu Nayyar** and **Mrs. Meena Nayyar**, whose countless sacrifices and endless love has made me who I am today in life. I thank my loving uncle & aunt, **Mr. Shiv Kumar Nayyar & Mrs .Honey Nayyar**, for filling my life with positivity and passion, and for their constant support.*

*I am very grateful to my father and mother in law, **Mr. Chetan Mehta** and **Mrs. Swati Mehta**, for their unconditional love, and for standing by my side in the need of the hour.*

*I also thank my siblings, **Mr. Kartikay Nayyar**, **Mr. Vinayak Nayyar** and **Miss. Pragya Nayyar** for their motivation and for being a constant source of strength.*

*I thank my husband, **Mr. Ameet Chetan Mehta**, for his unending love and support, being an inspiration to aim higher and for all his sacrifices. I am thankful to my postgraduate colleagues, **Dr. Savana Waikhom** and **Dr. Nishi Nagaria**, my seniors and dear juniors for all their love, motivation and help. I am truly blessed in having the most wonderful friends and would like to thank them for their endless support.*

*I will be failing my duty if I do not thank all my patients involved in this study, without whose co-operation and patience this study would have been impossible.*

*Last, but not the least, I would like to express my gratitude to the **Almighty** for all his blessings.*

Date:

Signature of candidate

Place: Kolar

**DR. CHANDRIKA NAYYAR**

## LIST OF ABBREVIATIONS

SL NO	ABBREVIATIONS	FULL FORMS
1	ALR	Ablative Laser
2	A F R	Ablative Fractional Resurfacing
3	bFGF	Basic fibroblast growth factor
4	cm <sup>-1</sup>	reciprocal centimeter
5	CO <sub>2</sub>	Carbon Dioxide
6	col	Collagen
7	CROSS	Chemical reconstruction of skin scars
8	°C	Degree Celsius
9	DOPA	3,4-dihydroxyphenylalanine
10	3D	Three Dimension
11	ECCA	Echelle d'Evaluation clinique des cicatrices
12	Er:YAG	Erbium Yttrium Aluminium Garnet
13	FDDA	Fractional Deep Dermal Ablation
14	FGF	Fibroblast growth factor
15	FrCO <sub>2</sub>	Fractional Carbon Dioxide Laser
16	Hz	Hertz
17	J	Joule
18	J/cm <sup>2</sup>	Joule per square centimeter
19	k H z	Kilo Hertz

20	KTP	Potassium-titanyl-phosphate
21	MHz	Millihertz
22	mJ	Millijoules
23	ml	Milliliters
24	mm	Millimeters
25	mm <sup>2</sup>	Square millimeters
26	ms	Milliseconds
27	mg	Milligrams
28	MNZ	Micronecrotic zone
29	MTZ	Microthermal Treatment Zone
30	MMP	Matrix metalloproteinase
31	μm	Micrometers
32	μs	Microseconds
33	nm	Nanometers
34	Nd:YAG	Neodymium-doped yttrium aluminium garnet
35	%	Percents
36	PLLA	Poly-L-lactic acid
37	PRP	Platelet-rich plasma
38	PDL	Pulsed Dye Laser
39	PIH	Post Inflammatory Hyperpigmentation

40	ROS	Reactive Oxygen Species
41	RF	Radiofrequency
42	YSGG	Yttrium-Scandium-Gallium-Garnet
43	W	Watts

## ABSTRACT

**Background:** Dark skin type has a high inclination to acne scarring and is frequently complicated by persistent erythema or pigmentation. Fractional CO<sub>2</sub> Laser injures the collagen with a monochromatic light beam, resulting in neocollagenesis, leading to resurfacing atrophic acne scars; however, prolonged erythema and post-inflammatory hyperpigmentation limit its usefulness, particularly in coloured skin. Vitamin C is famous for its anti-oxidant, anti-pigmentary, and wound healing properties. Laser-assisted drug delivery achieves greater penetration of topical agents. Recent literature demonstrates that ablative laser therapy and topical Vitamin C serum would optimize clinical outcomes in atrophic acne scars.

**Objectives:** The primary objective was to assess the efficacy and safety of Fractional CO<sub>2</sub> Laser as Monotherapy and Fractional CO<sub>2</sub> Laser in combination with Topical Vitamin C Serum in treating Atrophic Facial Acne Scars. Secondary objectives were to assess post-laser adverse effects and healing.

### **Material and Methods:**

The study was a double-blinded randomized trial among 76 subjects; 38 in Fractional CO<sub>2</sub> laser monotherapy (Group1) and 38 in the Fractional CO<sub>2</sub> Laser in combination with Vitamin C serum within 2 minutes immediately after Laser and daily for four months (Group 2). Patients with facial atrophic acne scar belonging to both sexes, within an age group of 18 -40 years, with moderate to severe scar, and willing to undergo treatment and follow up were included in the study. Participants underwent serial photography of the

lesions at baseline, 1 month, 2 months, 3 months, and 4 months from the first treatment session. The visual analog scale (scoring from 0 to 10) was used to record adverse events (erythema and edema) as perceived by participants. The final assessment was made subjectively by a single observer at the last follow-up visit, and a quartile grading scale was used to assess the response objectively. Data were entered into a Microsoft Excel datasheet and was analysed using SPSS 22 version software. Categorical data was represented in the form of Frequencies and proportions. The Chi-square test or Fischer's exact test (for 2x2 tables only) was used as a test of significance for qualitative data. Continuous data were represented as mean and standard deviation. MS Excel and MS word were used to obtain various graphs. P-value of  $<0.05$  was considered statistically significant after assuming all the rules of statistical tests.

**Results:** A statistically significant difference ( $p<0.001$ ) was found between the groups with respect to improvement in the appearance of scars after six months. 42.1% and 52.6% of Group 2 patients had  $>75\%$  and 50-75% of improvement. 21.1% and 31.6% of patients in Group 1 had  $>75\%$ , and 50-75% of improvement.  $>80\%$  of patients were either satisfied or very satisfied in both groups. A statistically significant difference ( $p<0.001$ ) was found between the groups regarding erythema and edema on Day 7 after the CO<sub>2</sub> laser therapy session. With a P-value of 0.016, a statistically significant difference was observed between the groups concerning side effects.

**Conclusion:** The combination of using an ablative fractional CO2 laser and Vitamin C serum in the treatment of atrophic scars has a synergistic effect on their inherent properties in up-regulating new collagen synthesis to improve atrophic scars. Erythema, edema, and post-laser downtime are significantly reduced, with diminished risk of adverse effects.

**Keywords:** Atrophic, Acne, Scar, Fractional, Healing, Pigmentation, Laser, Vitamin C



## **TABLE OF CONTENTS**

<b>Sl. No.</b>	<b>Content</b>	<b>Page No.</b>
<b>1.</b>	<b>INTRODUCTION</b>	<b>1</b>
<b>2.</b>	<b>AIMS AND OBJECTIVES</b>	<b>3</b>
<b>3.</b>	<b>REVIEW OF LITERATURE</b>	<b>4</b>
<b>4.</b>	<b>METHODOLOGY</b>	<b>46</b>
<b>5.</b>	<b>RESULTS</b>	<b>50</b>
<b>6.</b>	<b>DISCUSSION</b>	<b>77</b>
<b>7.</b>	<b>CONCLUSION</b>	<b>83</b>
<b>8.</b>	<b>SUMMARY</b>	<b>84</b>
<b>9.</b>	<b>BIBLIOGRAPHY</b>	<b>86</b>
<b>10.</b>	<b>ANNEXURES</b>	<b>103</b>
<b>11.</b>	<b>MASTER CHART</b>	<b>115</b>

## LIST OF TABLES

S. NO	TABLES	PAGE NO
1	ECCA grading scale	4
2	Goodman and Baron Quantitative Scarring Grading System	6
3	Assessment of Goodman and Baron Quantitative Scarring Grading System	7
4	Goodman and Baron Qualitative Scarring Grading System	38
5	Procedures to select by lesion type of Scars	50
6	Classification of Derma fillers	51
7	Overview of Lasers for Acne Scar	53
8	Ablative and non-ablative systems for acne scars treatment	55
9	Comparison of AFR, Sub-ablative resurfacing and non-AFR after irradiation.	57
10	Morphometric dimension of MTZs in response to three different treatment protocols.	59
11	Vitamin C content of skin in comparison to other tissue	60
12	Distribution of subjects according to age group between the groups.	61
13	Distribution of subjects according to gender between the groups.	62

	<b>LIST OF TABLES</b>	
14	Distribution of subjects according to marital status between the groups.	63
15	Distribution of subjects according to occupation between the groups	64
16	Patient Distribution according to fitzpatrick skin type between the groups	65
17	Distribution of subjects according to grading of scar between the groups.	65
18	Distribution of subjects according to improvement after 6months between the groups.	66
19	Distribution of subjects according to patient's satisfaction between the groups.	66
20	Comparison of edema on Day 1 and Day 7 at various session between two groups between the groups.	67
21	Comparison of erythema on Day 1 and Day 7 at various session between two groups between the groups.	
22	Distribution of subjects according to side effects between the groups	

## LIST OF FIGURES

S. NO	FIGURES	PAGE NO
Figure 1	The three types of atrophic acne scar: a) Icepick, b) Boxcar, and c) Rolling	22
Figure 2	Acne scar subtypes	24
Figure 3	Acne scars assessed by the ECCA grading scale	26
Figure 4	Diagram of Acne Scar Subtypes	35
Figure 5	Acne scarring treatment algorithm	69
Figure 6	Subcision technique done by undermine the fibrous connection under rolling scars	70
Figure 7	Piston-like motion: the technique for release the fibrous bands by advance the needle through them. 35	71
Figure 8	Hypertrophic scars developed after underwent CO2 laser resurfacing <sup>85</sup>	72
Figure 9	Patient underwent fulfill ablative resurfacing to treat perioral wrinkles with single pass of CO2 laser show diffuse erythema and crusting	73
Figure 10	Comparison of ablative skin resurfacing, nonablative dermal remodeling, and FP135	74
Figure 11	The difference of histological skin response after treatment with non- ablative fractional lasers and AFR	75

Figure 12	(a) types of acids used in the depth of penetration of fractional lasers on the facial skin (b) Comparison of the dose and depth with AFR. (c) A comparative MTZ lesion reconstruction plots of three fractional lasers.	76
Figure 13	Superficial fractional RF tip	22
Figure 14	Microscopic ablation zone	24
Figure 15	Chemical structure of ascorbic acid	26
Figure 16	Antioxidant Role of Vitamin C155	35
Figure 17	Delivery of Nutrients to the Skin. SVCT1 and SVCT2 are the transporter proteins of Vitamin C	69
Figure 18	GROUP 1- Case 1 Front Face Profile	70
Figure 19	GROUP 1- Case 1 Right Face Profile	
Figure 20	GROUP 1- Case 1 Left Face Profile	
Figure 21	GROUP 1- Case 2 Front Face Profile	
Figure 22	GROUP 1- Case 2 Right Face Profile	
Figure 23	GROUP 1- Case 2 Left Face Profile	
Figure 24	GROUP 2- Case 1 Front Face Profile	
Figure 25	GROUP 2- Case 1 Right Face Profile	
Figure 26	GROUP 2- Case 1 Left Face Profile	
Figure 27	GROUP 2- Case 2 Front Face Profile	
Figure 28	GROUP 2- Case 2 Right Face Profile	
Figure 29	GROUP 2- Case 2 Left Face Profile	

## LIST OF GRAPHS

S. NO	GRAPHS	PAGE NO.
Graph 1	Distribution of subjects according to age group between the groups	50
Graph 2	Distribution of subjects according to gender in group 1	52
Graph 3	Distribution of subjects according to gender in group 2	54
Graph 4	Patient Distribution according to marital status between the groups.	56
Graph 5	Patient Distribution according to occupation between the groups	58
Graph 6	Patient Distribution according to fitzpatrick skin type between the groups.	59
Graph 7	Patient Distribution according to grading of scar between the groups.	60
Graph 8	Patient Distribution according to improvement in appearance of scars after 6 months	61
Graph 9	Patient Distribution according to patient's satisfaction between the groups.	62
Graph 10	Comparison of edema on Day 1 at various session between two groups between the groups	63

	<b>LIST OF GRAPHS</b>	
Graph 11	Graph showing Comparison of edema on Day 7 at various session between two groups between the groups.	64
Graph 12	Comparison of erythema on Day 1 at various session between two groups between the groups.	67
Graph 13	Graph showing Comparison of erythema on Day 7 at various session between two groups between the groups.	68
Graph 14	Patient Distribution according to Side Effects between the groups	

# INTRODUCTION





---

## INTRODUCTION

Acne vulgaris is a chronic inflammatory disease commonly found in a patient during adolescent years, young adults and can even persist through later adulthood.<sup>1</sup> It is clinically characterized by pleomorphic lesions like comedones, papules, pustules, nodules, and cysts.<sup>2</sup> In addition, seborrheic areas like the face, upper chest, and back of the trunk are usually affected.<sup>3</sup> The primary pathogenesis of acne is increased sebum production, colonization of *Cutibacterium acnes*, follicular hyperkeratinization, and peri-follicular inflammation, which can damage the skin and result in scarring.<sup>1-4</sup>

Acne was initially presumed to be merely a cosmetic affliction. However, the psychosocial effects of the disease have now been scientifically proven.<sup>5, 6</sup> Studies have shown these effects to improve when acne is treated.<sup>6,7</sup> Acne scars of the face are seen in approximately 20% of teenagers. This facial scarring, especially in males, is identified to be a risk factor for suicide.<sup>4-7</sup>

There are mainly two basic types of scars after the healing of acne.<sup>7</sup> In up to 80 percent of the cases, atrophic scars occur, while the rest develop hypertrophic scars or keloid—various atrophic scars; maybe soft and distensible or fibrotic.<sup>8</sup> For months, these scars tend to sustain a vascular hue before becoming less evident. Atrophic scars can be sub-classified into three subtypes; rolling scar, box scar, and ice pick scar.<sup>7-9</sup> Each has its characteristics and responds differently to the same treatment modality.<sup>7</sup>

Multiple modalities have been introduced in treating acne scars, such as

---

chemical peels, dermabrasion, laser treatment, dermal grafting, tissue augmentation, needling; there is still no definitive guideline in treating acne scars.<sup>8</sup> Over the last few years, laser therapies for acne scarring have become popular because of their remarkable outcomes.<sup>16</sup> Combining different methods improves the efficacy of acne scars and decreases the downtime and inflammation associated with laser treatment.<sup>7-9</sup>

Lasers for acne scars can be divided into two major categories, the ablative laser, and the non-ablative laser.<sup>10,11</sup> An ablative laser is more efficacious in treating facial imperfections, but its disadvantages, such as peri-procedure discomfort and longer recovery time, have become their most significant limitation.<sup>11-13</sup> On the contrary, a Non-ablative laser is more tolerable with a shorter recovery time, but multiple treatment sessions are required and provide less impressive results than traditional ablative lasers.<sup>14</sup> Examples of Ablative lasers are CO2 lasers, Er: YAG lasers, and Non-ablative lasers are Nd: YAG laser and diode lasers.<sup>11</sup>

The laser operates by remitting a monochromatic light within the scar, which heats and injures the collagen, resulting in neocollagenesis.<sup>10</sup> Fractional laser has been introduced in the field of laser to reduce the disadvantages of those traditional ablative lasers made while trying to maintain the high efficacy in resurfacing the skin.<sup>11,15</sup> The fractional lasers function by delivering the laser beam on the affected skin in 'fractions' by omitting intervening regions of skin untreated.<sup>13-15</sup> This ensures rapid re-epithelisation by the untreated areas; furthermore, the risk of extended and severe adverse effects is

---

minimized<sup>15</sup>.

Resurfacing atrophic acne scars is stimulated by wound remodelling simultaneously with the synthesis of new collagen and elastin utilizing a Fractional CO<sub>2</sub> Laser.<sup>12-15</sup> There is an increased generation of Myofibroblasts along with matrix proteins example: hyaluronic acid.<sup>11,12</sup> The restrained dermal injury diminishes the possibility of further scarring due to a high-energy, short-duration exposure of 10,600 nm CO<sub>2</sub> laser light that evaporates intra- and extracellular water, causing tissue ablation rapidly to decrease injury.<sup>11-15</sup>

The inhibitory effect of Vitamin C on melanogenesis has been hypothesized.<sup>16,17</sup> Therefore, Vitamin C might be beneficial for post-inflammatory hyperpigmentation following laser skin rejuvenation.<sup>18-20</sup> At the molecular level, the expression of basic fibroblast growth factor (bFGF) was remarkably increased in the treatment of facial acne scars.<sup>17,19</sup> Post-laser use of Vitamin C combined with Vitamin E and Ferulic acid was delivered, resulting in reduced edema compared to the control group. Poor wound healing is associated with Vitamin C deficiency.<sup>16-19</sup> Vitamin C aids in collagen synthesis and additionally has an antioxidant effect.<sup>21</sup> A sufficient supply of antioxidants is present within Vitamin C Serum, which benefits Optimal skin health.<sup>20,21</sup>

In the case of acne scars, the fractional resurfacing CO laser gives excellent results.<sup>22,23</sup> However, the prolonged erythema lasting for weeks, crusting and

---

oozing, and post-inflammatory hyperpigmentation are recognized side effects associated with these treatment modalities, particularly in the coloured skin, limiting the usefulness of this option.<sup>23,24</sup> The technology of fractional CO<sub>2</sub> laser avoids many undesirable effects as only a "fraction" of the skin is shot, and the epidermis and its integrity are not compromised.<sup>23,24</sup> For that, the microscopic wound produced by the laser beams is enclosed by normal, unlasered tissue, the healing is quick, and the unwanted side effects are minimized.<sup>24</sup>

Antioxidants in the skin are considerably exhausted after the epithelium is triggered by fractional CO<sub>2</sub> laser therapy.<sup>23-25</sup> Therefore, the utilization of Vitamin C may be impactful to replenish depleted antioxidants and promote wound healing.<sup>25,26</sup> In addition, a laser-assisted delivery system can achieve excellent penetration of Topical Vitamin C Serum deep into the skin.<sup>26-29</sup>

Very few studies have been done where a combination of Fractional CO<sub>2</sub> Laser with Topical Vitamin C Serum is used; this study will help us determine their synergistic effect in treating facial acne scars.

# **AIMS & OBJECTIVES**



---

## OBJECTIVES

### **Aims and Objectives of the Study:**

1. To Assess the efficacy and safety of Fractional CO<sub>2</sub> Laser as Monotherapy and Fractional CO<sub>2</sub> Laser in combination with Topical Vitamin C Serum in the treatment of Atrophic Facial Acne Scars.
2. To Assess post laser adverse effects and healing of Fractional CO<sub>2</sub> Laser as Monotherapy and Fractional Co<sub>2</sub> Laser in combination with Topical Vitamin C Serum in the treatment of Atrophic Facial Acne Scars.

---

# **REVIEW OF LITERATURE**

A decorative graphic consisting of a thick horizontal line and a thick vertical line intersecting at the right end of the horizontal line, positioned below the title.



---

## REVIEW OF LITERATURE

Scarring on visible areas such as the face and neck can be associated with negative psychological impacts. Acne vulgaris affects 80% of people between the ages 11-30 years old and 5% in adults over 30 years of age.<sup>8,30</sup> Acne can be considered as a chronic disease in view of the older and the most recent definitions of chronicity by the World Health Organization.<sup>31</sup> Multiple treatment modalities have been introduced for the treatment of acne scars.<sup>32</sup>

### Pathogenesis

The main pathogenesis of acne is an increase in sebum production, colonization of *Cutibacterium acnes*, follicular hyperkeratinization, and perifollicular inflammation, all of which can damage the skin and result in atrophic or hypertrophic scars.<sup>33,34</sup> During the healing process, scars become atrophic due to the net degradation of the collagen fibers. On the other hand, collagen gain causes the scar to become hypertrophic or keloid.<sup>33-36</sup>

### Classification

There are mainly two types of the scar; in up to 80 percent of the cases, atrophic scars occur, while the rest develop hypertrophic scars or keloid. According to their morphology, atrophic acne scars are subdivided into three types: icepick, rolling, and boxcar. (Figure 1)<sup>35,36</sup>

---


**Figure 1: The three types of atrophic acne scar: a) Icepick, b) Boxcar, and c) Rolling <sup>35</sup>**



Sub-classification of atrophic scars aid the clinicians in choosing an adequate treatment for each type of scar.<sup>36</sup> Icepick scars are very resistant to conventional treatment.<sup>55-57</sup> Icepick scars are V-shaped epithelial tracts with a sharp margin extending downwards to the deep dermis or subcutaneous tissue with less than 2mm. They are the most common subtype and are seen in up to 70 percent of all the scar types.<sup>35,36</sup> In about 20-30 percent of scars, box scars are observed, characterized by round to oval depressions with a diameter between 1.5 to 4.0 mm, and they are the second most common subtype.<sup>32,36</sup> Rolling scars have a unique feature of fibrous anchoring of the dermis down to subcutaneous; they are the least common type, seen in about 15- 25 percent, characterized by superficial shadowing and undulating appearance with a diameter up to 5 mm (Figure 2)<sup>36-43</sup>

---

**Figure 2: Acne scar subtypes (adapted from Fabbrocini and his team)<sup>36</sup>**



## **Evaluation**

Commonly used grading scales are the ECCA grading scale and Goodman and Baron qualitative and quantitative global scarring grading system.<sup>39-41</sup>


### **1. ECCA grading scale**

ECCA grading scale (échelle d'évaluation Clinique des cicatrices d'acné) is a tool designed to evaluate the efficacy of the treatments on acne scars; it helps dermatologists in their everyday lives practice. Grading is composed of 6 items corresponding to 6 types of acne scars, with each kind of scar associated with a quantitative score ranging from 0 to 4 and a weighting factor ranging from 15 to 50. (Table 1) (Figure 3)<sup>39</sup>

**Table 1: ECCA grading scale** <sup>39</sup>

Description	Weighting factor (a)	Semi-quantitative score (b)	Grading (a × b)
V-shaped atrophic scars, diameter of less than 2 mm, and punctiform	15	0 = no scar 1 = a few scars 2 = limited number of scars 3 = many scars	/____/
U-shaped atrophic scars, diameter of 2–4 mm, with sheer edges	20	0 = no scar 1 = a few scars 2 = limited number of scars 3 = many scars	/____/
M-shaped atrophic scars, diameter of more than 4 mm, superficial and with irregular surface	25	0 = no scar 1 = a few scars 2 = limited number of scars 3 = many scars	/____/
Superficial elastolysis	30	0 = absent 1 = mild 2 = moderate 3 = intense	/____/
Subgrading 1			/____/
Hypertrophic inflammatory scars, scars of less than 2 years of age	40	0 = no scar 1 = a few scars 2 = limited number of scars 3 = many scars	/____/
Keloid scars, hypertrophic scars, of more than 2 years of age	50	0 = no scar 1 = a few scars 2 = limited number of scars 3 = many scars	/____/
Subgrading 2			/____/
Global score (subgradings 1 + 2)			/____/

**Figure 3: Acne scars assessed by the ECCA grading scale.<sup>39</sup>**



---

## **2. Goodman and Baron quantitative scarring grading system**

Goodman and Baron's quantitative scarring grading system classified scars into four types, i.e., mild atrophic scars, moderate atrophic scars, severe atrophic scars, and hypertrophic/keloidal post acne scars. Atrophic scars are scored according to the number of lesions the patient has. For example, mild atrophic scars are scored less heavily than moderately atrophic scars and, again, lesser than severe atrophic scars. On the other hand, hypertrophic/keloidal post acne scars are scored according to the area of the skin involvement.<sup>41</sup> (Table 2) (Table 3)

## **3. Goodman and Baron qualitative scarring grading system**

Goodman and Baron's qualitative scar grading system concentrates more on the scar morphologies and disease severity by dividing acne scars from the least severe to the most severe into four grades like grade 1, grade 2, grade 3, and grade 4. The patient will be described according to the highest grade, omitting the milder disease if the lesions on the patient's face are sub-classified into two or more grades.<sup>40</sup> (Table 4)

---

**Table 2: Goodman and Baron Quantitative Scarring Grading System<sup>41</sup>**

(Grade) Type	Number of lesions: 1 (1–10)	Number of lesions: 2 (11–20)	Number of lesions: 3 (> 20)
(A) Milder scarring (1 point each)	1 point	2 points	3 points
Macular erythematous or pigmented			
Mildly atrophic dish-like			
(B) Moderate scarring (2 points each)	2 points	4 points	6 points
Moderately atrophic dish-like			
Punched out with shallow bases small scars (< 5 mm)			
Shallow but broad atrophic areas			
(C) Severe scarring (3 points each)	3 points	6 points	9 points
Punched out with deep but normal bases, small scars (< 5 mm)			
Punched out with deep abnormal bases, small scars (< 5 mm)			
Linear or troughed dermal scarring			
Deep, broad atrophic areas			
(D) Hyperplastic	2 points	4 points	6 points
Papular scars			
(D) Hyperplastic	Area < 5 cm <sup>2</sup> 6 points	Area 5–20 cm <sup>2</sup> 12 points	Area > 20 cm <sup>2</sup> 18 points
Keloidal/hypertrophic scars			

**Table 3: Assessment of Goodman and Baron Quantitative Scarring Grading System<sup>41</sup>**

Assessment of	Goodman and Baron Quantitative Scarring Grading System
0-5	Minimal Reduction in GSGS Score
5-10	Moderate Reduction in GSGS Score
10-15	Good Reduction in GSGS Score
>15	Very Good Reduction in GSGS Score

**Table 4: Goodman and Baron Qualitative Scarring Grading System<sup>40</sup>**

Grade	Level of disease	Characteristics	Examples of scars
1	Macular disease	Erythematous, hyper- or hypopigmented flat marks visible to patient or observer irrespective of distance.	Erythematous, hyper- or hypopigmented flat marks
2	Mild disease	Mild atrophy or hypertrophy that may not be obvious at social distances of 50 cm or greater and may be covered adequately by makeup or the normal shadow of shaved beard hair in males or normal body hair if extrafacial.	Mild rolling, small soft papular
3	Moderate disease	Moderate atrophic or hypertrophic scarring that is obvious at social distances of 50 cm or greater and is not covered easily by makeup or the normal shadow of shaved beard hair in males or body hair if extrafacial, but is still able to be flattened by manual stretching of the skin.	More significant rolling, shallow "box car," mild to moderate hypertrophic or papular scars
4	Severe disease	Severe atrophic or hypertrophic scarring that is obvious at social distances of 50 cm or greater and is not covered easily by makeup or the normal shadow of shaved beard hair in males or body hair (if extrafacial) and is not able to be flattened by manual stretching of the skin.	Punched out atrophic (deep "box car"), "ice pick", bridges and tunnels, gross atrophy, dystrophic scars significant hypertrophy or keloid



---

## **Treatment**

In the same visit, combination therapy may be necessary for treating atrophic acne scars to achieve the best result. Multiple modalities have been introduced to treat atrophic acne scars, such as chemical peels, dermabrasion, laser treatment, dermal grafting, tissue augmentation, needling, excision, and fat transplantation.<sup>8-10</sup> Each type of acne scar responds differently to each treatment option. Therefore physical examination to evaluate each patient is an essential procedure.<sup>44</sup>(Figure 4)


The first step of treating acne scars is to decrease the redness with vascular lasers such as PDL, IPL, or KTP. Therefore initial assessment of residual erythema is done at the first visit, following that clinician addresses whether the patient has generalized or individual scars.<sup>8</sup> The scars are then treated as per the most suitable option. Lasers and resurfacing agents remain the mainstay of treatment for generalized areas of scarring. For individual scars, injectable fillers or surgical procedures are more appropriate.<sup>43</sup> (Figure 5)

Each type of scar responds to each treatment differently; fractional photothermolysis is the only effective treatment in all kinds of scar. In contrast, other treatment modalities can provide more negligible or no effect in one type of scar.<sup>43-45</sup> Ablative laser resurfacing is one of the most popular choices in treating generalized atrophic acne scars because of its ability to reduce all types of scars compared to other treatment modalities. Ablative lasers may lack efficacy in some scars.<sup>46-48</sup>


---

Additionally, techniques such as subcision and tissue augmenting agents can provide effective treatment in all types of scars, but less in comparison to fractional photothermolysis and are also more suitable in patients with individual scars.<sup>49,50</sup> (Table 5)

**Figure 4: Diagram of Acne Scar Subtypes<sup>36</sup>**



**Figure 5 : Acne scarring treatment algorithm<sup>43</sup>**



**Table 5: Procedures to select by lesion type of Scars<sup>49,50</sup>**

TABLE 2. Procedures to select by lesion type of scars			
TREATMENT	ICE PICK SCARS	ROLLING SCARS	BOXCAR SCARS
Chemical peels TCA CROSS technique	++ ++	--	++ ++
Dermabrasion/microdermabrasion	+	-	+
Laser Ablative and nonablative laser Fractional photothermolysis	- ++	+++	+++
Punch techniques Punch excision Punch elevation Punch replacement grafting	++ - ++	---	+ ++ -
Tissue augmenting agents	+	++	+
Needling	-	++	++
Subcision	+	++	+
++ = Effective, + = less effective, - = not effective			

---

A physician must consider the following while treating acne scars<sup>45-49</sup>

- Cost
- Severity of lesions
- Physician expectations
- Patient expectations
- Side effects
- Duration between treatment sessions.

The aim of treatment is improvement in the appearance of the scar, not for a complete cure.<sup>46-49</sup> The current treatment modalities of atrophic acne scar include chemical peels, subcision, punch techniques, dermabrasion/microdermabrasion, dermal punch grafting, tissue augmented grafting (fat transplantation), other tissue augmented grafting (such as autologous collagen, bovine collagen, hyaluronic acid injection), platelet-rich plasma, plasma skin regeneration, and laser skin resurfacing.<sup>49-52</sup> The treatment options may be categorized into five main categories: medical management, procedure management, surgical management, tissue augmentation, and combination therapy.<sup>45-52</sup>

---

## **1. Medical Management**

Topical retinoids, topical/injectable corticosteroids, and other topical or injectable substances such as vitamin A, vitamin C, vitamin E, zinc, colchicine, cyclosporine, honey, and onion extract, and 5-fluorouracil are the current medical options available.<sup>10, 51-54</sup>

Topical retinoids are helpful mainly in treating very superficial scars and also preventing scars.<sup>55</sup> Hypertrophic scars and keloid are commonly treated with intralesional corticosteroids, reducing cellular adhesion molecules and enzymes related to the inflammatory process.<sup>53,56</sup> Hypertrophic scars, keloids, and post-acne pigmentary changes focus on medical management, but the atrophic scars need other forms of intervention.<sup>50-56</sup>

## **2. Surgical Management**

The surgical treatments are mainly recommended for icepick, boxcar, and rolling scars.<sup>54</sup> There are multiple available techniques for surgical management in atrophic acne scars.

### **(1) Punch Excision**

The icepick and deep boxcar scars primarily utilize punch excision to eliminate the deeper portions, enabling fewer passes of laser treatment; therefore, it is beneficial.<sup>37</sup> The diameter of the scar walls should be equal to the diameter of the punch biopsy instrument.<sup>57</sup> The distance between two lesions should be at least 4-5 mm to prevent excess traction and lack of

---

proper wound eversion.<sup>58</sup> Punch elevation or elliptical excision is preferred to avoid a “dog-ear” appearance if the scar requires a larger punch.<sup>31,95-98</sup>

## **(2) Punch Grafting**

Punch Grafting is a combination of punch excision followed by full-thickness skin grafts used to treat deep icepick acne scars.<sup>95, 96</sup> Mismatch in color and thickness of grafts with normal surrounding skin is one of the disadvantages of this method.<sup>57,58</sup>

## **(3) Punch Elevation**

Initially, the punch biopsy instrument, whose size fits the inner diameter of the scar, is used to explore the scar down to the subcutaneous tissue. Subsequently, the scar base is carefully elevated slightly higher than the surrounding skin.<sup>57</sup> This technique is best employed for shallow and deep boxcar scars with normal skin appearance on the scar base.<sup>58</sup> The absence of risk of colour or texture mismatch is the main advantage of this method.<sup>55-58</sup>


## **(4) Subcision**

The technique uses a hypodermic needle probing beneath the lesion through the puncture movement and causes the breaking of the papillary dermis from the fibrous connections of the SMAS and produces minor injury that commences to the wound healing process (Figure 6 and 7).<sup>59</sup> It is the idealistic choice for rolling or depressed scars. However, subcision is not a true incision. This method may require multiple attempts or sessions.<sup>60,61</sup>

---

Most authors recommend combining the surgical with other modalities for a better treatment outcome. However, these are mainly used for initial debulking.<sup>10, 37</sup>

**Figure 6: Subcision technique done by undermine the fibrous connection under rolling scars <sup>35</sup>**



---

**Figure 7: Piston-like motion: the technique for release the fibrous bands by advance the needle through them. <sup>35</sup>**





---

### **3. Procedural Management**

The general group of therapies consists of chemical peels, dermabrasion and microdermabrasion, electrodesiccation, cryosurgery, and laser treatment in treating atrophic acne scar.

#### **(1) Chemical Peels**

A good candidate for this procedure is a patient with mild scars.<sup>37</sup> The mechanism damages a part or entire epidermis, with or without the dermis, leading to exfoliation and removal of superficial lesions, stimulating the epidermal and dermal tissue remodeling. However, various treatments are required for efficacy.<sup>61, 62</sup> Combination therapies are generally used to improve effectiveness.<sup>62</sup> Chemical peeling is a popularly practiced procedure in the outpatient clinic. Chemical peels can be divided into four different types-

CROSS (chemical reconstruction of skin scars) technique/ dot peeling, with high strength of TCA, is a beneficial and easy office procedure.<sup>59</sup> It is best fitted to treat ice pick or small boxcar scars. A fine toothpick is used to apply 65-100% TCA to the bottom of scars, leading to collagenization and filling up the atrophic scars.<sup>63, 64</sup>

---

## **(2) Dermabrasion and Microdermabrasion**

The technique mechanically ablates damaged skin to promote re-epithelialization using a high-speed diamond cylinder brush or manual silicone carbide sandpaper.<sup>65-67</sup> The re-epithelialization occurs by migrating stem cells from adnexal structures to the healing Surface.<sup>14, 68</sup> The superficial treatment eliminates the epidermis, and the deep treatment removes the epidermis and papillary or reticular dermis<sup>30, 69</sup>. The treatment modality produces a clinically significant improvement in skin texture and acne scars.<sup>43</sup> Microdermabrasion is less invasive than dermabrasion as it is a more superficial painless form of dermabrasion but has a lesser effect than dermabrasion and, therefore, cannot manage deep scars.<sup>36</sup> The drawback of dermabrasion is the scarcity of adnexal structure in the neck, chest, and back areas that are not ideally suited for treatment.<sup>65-68</sup>

## **(3) Cryosurgery and Electrodesiccation**

Cryosurgery causes physical damage by locally enhancing the cell damage and thrombosis of the vessel in lesions using a liquid nitrogen spray. Skin atrophy or hypopigmentation are the possible side effects.<sup>70</sup> Cryosurgery is mainly used for treating keloids and hypertrophic scars.<sup>118</sup> The mechanism of electrodesiccation is thermal tissue damage and coagulation by using electrical probes.<sup>53</sup> Electrodesiccation helps shape the edge of boxcars scars and usually is adjunctive treatment because of the significant risk of developing new scars.<sup>70</sup>

---

#### **(4) Combination Therapy**

There are multiple approaches to combining acne scars treatment modalities, commonly chemical peels, with procedure management. Dot peeling TCA, followed by subcision, and, in the end, fractional laser resurfacing are commonly employed triple combination therapy that is a safe and efficient treatment of a variety of scars for a duration of 12 months.<sup>10, 58-69</sup> Twice every 2-3 months, dot peeling and subcision, were performed, and fractional laser resurfacing was conducted in the interval of 3-4 weeks.<sup>61</sup>

Currently, many studies concentrate on platelet-rich plasma (PRP), an autologous concentration of human platelets contained in a small volume of plasma as one of the combination procedures.<sup>66,71</sup> Ibrahim ZA and his colleagues found higher efficacy and safety with a combination of microdermabrasion and autologous PRP in treating acne scars rather than alone.<sup>71</sup> With fractional laser treatment, such as FrCO<sub>2</sub>, PRP is also a good combination for skin rejuvenation.<sup>72</sup> The benefit of the combination was evident in numerous aspects, including the rapidity and degree of improvement of the atrophic acne scars, lesser side effects, and shorter post-operative recovery groups.<sup>10,36, 73</sup>

#### **(5) Tissue Augmentation**

There are many available autologous, non-autologous biologic, and non-biologic tissue augmentation agents used to treat atrophic scars.<sup>74</sup> as classified in Table 6.

---

**Table 6: Classification of Derma fillers<sup>74</sup>**

<b>Filler class</b>	<b>Average clinical efficacy</b>	<b>Examples</b>
<b>Temporary</b>	<b>3–18 months</b>	<b>Hyaluronic acid and collagen</b>
<b>Semi-permanent</b>	<b>Up to 24 months</b>	<b>Poly-l-lactic acid and calcium hydroxylapatite</b>
<b>Permanent</b>	<b>Many years if not lifelong</b>	<b>Silicon, polyacrylamide, polymethacrylate, and hydroxyethylmethacrylate</b>

Dermal fillers efficiently treat rolling scars.<sup>36, 74</sup> There are two techniques- First, fillers are directly given beneath individual scars. Second, they are used for increasing volume into the laxity or deep tissue atrophy to accentuate the appearance of acne scars such as Poly-l-lactic acid (PLLA) or calcium hydroxyapatite.<sup>74-76</sup> It is hypothesized that PLLA stimulates endogenous fibroblast and subsequently causes collagen production.<sup>126</sup>


Various tissue augmentation agents used in the past are at high risk of developing side effects.<sup>127</sup> Hyaluronic acid is a glycosaminoglycan polysaccharide and a component of the extracellular matrix.<sup>74-76</sup> Many types of Hyaluronic acid fillers differ in their percentage of cross-linking, cross-linking technology, the ratio of hyaluronic acid and bound water, hardness, viscosity, modulus, swelling, particle size, gel to fluid ratio, and ease of injection.<sup>77</sup> The microinjection of low viscosity hyaluronic acid is a valuable

technique for treating superficial depressed scars.<sup>78</sup> Currently, hyaluronic acid is recommended as it can improve the longevity of treatment by stimulating fibroblasts to produce collagen and reduce the risk of immunogenicity and hypersensitivity.<sup>77,78</sup> Unavoidable side effects are mild-to-moderate pain during injection.<sup>78</sup>

**(6) Laser Treatments for Acne Scars**

The laser resurfacing, ablative, sub-ablative and non-ablative, have been proved to be helpful for patients with boxcar and rolling scars for homogenized overall skin texture.<sup>24, 79</sup>

**Table 7: Overview of Lasers for Acne Scar<sup>79</sup>**



---

## **(1) Ablative Laser**

The most commonly used ALR are CO<sub>2</sub> laser and Erbium: Yttrium-Aluminum-Garnet laser (Er:YAG). The CO<sub>2</sub> laser was first developed in 1964 by Patel and colleagues in the Bell Labs, USA.<sup>80</sup> It emits infrared beam at the 10,600 nm wavelength which is strongly absorbed by water-containing tissue.<sup>81-87</sup> It cause tissue evaporation and may cause immediate contraction of the ablated areas by denaturing existing old collagen.<sup>88-93</sup> The continuous wave CO<sub>2</sub> laser is the gold standard in ablative lasers.<sup>94-99</sup> The indication for using CO<sub>2</sub> laser (absorption coefficient 800 cm<sup>-1</sup>) for treatment are actinic and seborrheic keratosis, wart, skin tags, epidermal and dermal melanocytic nevi and xanthelasma.<sup>100-112</sup>

Other conditions that have been shown to respond to CO<sub>2</sub> laser resurfacing include dermatofibroma, rhinophyma, severe photodamage, sebaceous gland hyperplasia, syringoma, actinic cheilitis, angiofibroma, depressed scar, hypertrophic/keloid scar, neurofibroma, pyogenic granuloma, and pearly penile papules.<sup>112-117</sup> The minor complications that frequently occur are PIH, milia formation, perioral dermatitis.<sup>118-123</sup> More serious complications include skin infection (bacteria, virus, candida), hypopigmentation, and persistent erythema. The most severe complications are hypertrophic scarring (Figure 8), disseminated infection, and ectropion.<sup>85,123-127</sup>

---

**Figure 8: Hypertrophic scars developed after underwent CO2 laser resurfacing<sup>85</sup>**



The short-pulse, high-peak power, rapidly continuous wave CO2 and normal mode Er:YAG laser are developed after the traditional CO2 laser, they are increase in the accuracy for ablate the tissue layers.<sup>13</sup>

The Er:YAG laser emits light at the 2,940 nm wavelength in the infrared range which is closer to the peak absorption range of water and produce greater absorption coefficient than CO2 laser result in more precise ablation of skin and less side effects ( $12,800 \text{ cm}^{-1}$ , 12-18 times more efficiently absorbed by water than CO2 laser).<sup>128,129</sup> The pulse duration of Er:YAG is 250  $\mu\text{s}$  which is much shorter than that of CO2 laser, resulting in decrease thermal effect and less effect of hemostasis.<sup>129</sup> In spite of greater absorption coefficient, both CO2 laser and Er:YAG laser has similar efficacy from the

---

comparative study, the reason may be the reduction of amount of collagen contraction due to the reduction of collagen reduction.<sup>130</sup> The variable pulse Er:YAG laser is developed to correct the disadvantages of conventional Er:YAG laser by add hemostasis ability and dermal collagen remodeling induction. No significant different in efficacy of old and new version of Er:YAG.<sup>131</sup> The Er:YAG can be used for the treatment of dyschromia, photoaging, scars, wrinkle, coarse skin texture and skin laxity.<sup>128-131</sup>

However, there is controversy that the CO<sub>2</sub> laser may have superior advantage in tightening skin tissue while producing more adverse events (oozing, bleeding, crusting, prolonged downtime post procedure (about one week or more) (Figure 9), acne, persistent erythema, post inflammatory hyper-, and hypopigmentation and infection.<sup>107-129</sup>



---

**Figure 9: Patient underwent full ablative resurfacing to treat perioral wrinkles with single pass of CO2 laser show diffuse erythema and crusting.**



---

## **(2) Non-ablative Laser**

Due to the complications of ablative lasers, most of patients tend to receive the skin resurfacing treatments with non-ablative lasers which produce less side effects. The most common used are Neodymium-doped yttrium aluminum garnet Nd:YAG, 1540-nm erbium glass laser and diode lasers.<sup>133</sup> They remain intact tissue surface and stimulate new collagen formation. The 532-nm potassium titanyl phosphate (KTP) laser and the 585 to 595-nm pulsed dye lasers (PDL) also used for rejuvenation, however there are much better for the vascular lesions but little effects on collagen and elastin.<sup>45-56</sup> Q-switched Nd:YAG 1064-nm laser also has been shown to stimulate dermal remodeling for either original version and combined with a carbon particle solution version.<sup>30-50</sup> Although the non-ablative procedures produce minimize side effects, the improvement is not as impressive as in ablative laser resurfacing.<sup>53-65</sup> The ablative and non-ablative systems for acne scars treatment are summarized in Table 8.

---

**Table 8: Ablative and non-ablative systems for acne scars treatment<sup>10,13</sup>**

LASER TYPES	WAVELENGTH (nm)	FLUENCE (J/cm <sup>2</sup> )	PULSE DURATION	SPOT SIZE (mm)
<b>ABLATIVE LASERS</b>				
CO <sub>2</sub> laser (Ultrapulse 100 W, individual pulse)	10,600	5-7	<950 $\mu$ s	3 Collimated beam
CO <sub>2</sub> laser (Scanned >20 W, spiral or rasterized scan)	10,600	5-15	0.03–0.52-sec scan duration 300–1000 $\mu$ s dwell time	0.6- to 15-mm scan size with 0.1- to 0.25-mm focused beam
Er:YAG (Individual pulses)	2,940	0.001- 0.05	300 $\mu$ s to 10 ms	2- to 7-mm collimated or focus beam
<b>NONABLATIVE LASERS</b>				
KTP laser	532	15	20 ms	10
PDL	585/595	3/6-8	350 microns/6 ms	5/10
Nd:YAG	1064/1320	50/18	50/18 ms	12/6
Diode	1450	8-14	250	6
Er:glass	1540	Up to 126	3.3 ms	4

### (3) Fractional Photothermolysis


'Fractional Photothermolysis' is a term given by Rox Anderson, MD, and Reliant Technologies (Mountain View, Calif).<sup>134</sup> Ablative FP is a recently developed technology that is an effective modality and overcomes the disadvantages of conventional ablative laser.<sup>135</sup>

The FP technique creates the MTZ, characterized by microscopic wounds, as demonstrated in Figure 10, surrounded by uninjured tissue. MTZs resemble multiple minute dots on the skin, but they are revealed as columns or

---


cylinders of the epidermal and dermal thermal damage on histological examination. After laser radiation, tissue commences healing rapidly. The benefits of this technique are a short recovery period and fewer side effects such as PIH, post-inflammatory hypopigmentation, scarring.

**Figure 10: Comparison of ablative skin resurfacing, nonablative dermal remodeling, and FP<sup>135</sup>**



The fractional lasers are classified as nonablative and ablative fractional resurfacing (AFR) lasers with different histological characteristics. The nonablative fractional lasers create a nonablative micronecrotic zone (MNZ) surrounded by unaltered, normal tissue, while the AFR forms micro ablative columns (MAC), affecting both epidermis and dermis. The re-epithelialization is usually achieved in 2-3 days.<sup>80</sup> (Figure 11).

**Figure 11: The difference of histological skin response after treatment with non- ablative fractional lasers (left picture) and AFR (right picture). The non-ablative fractional lasers produce non-ablative MNZ surrounded by unaffected normal tissue. The AFR produce MAC which involve both epidermis and dermis.<sup>80</sup>**




---


The indications of fractional technology are chronic photodamage, skin laxity, rhytides, multiple types of scarring: acne scars, hypopigmented scars, surgical scars, and facial melasma.<sup>13</sup> Atrophic acne scars are frequently treated with fractional erbium glass 1550/1540 nm laser as a nonablative fractional laser, and fractional 2940- nm Er: YAG laser along with fractional 10,600-nm CO2 laser as ablative fractional laser resurfacing (AFR).<sup>135, 136</sup> Most fractional lasers have depth- with a ratio of MTZ about 4-5. The more depth reached by fractional lasers, the more the laser's efficacy achieved for the deep scars.<sup>135</sup> (Figure 12) Before treating acne scars, it is essential to consider the depth of scars. Since maximum scars are mixed type (Figure 12a), the ultimate efficacy of fractional lasers depends on the most predominant type of scars and laser used.<sup>137</sup>

Using a higher density performs more remarkable improvement in texture, tone, and dyspigmentation.<sup>137</sup> Moreover, the increase of pulse energies and fractional deep dermal ablation (FDDA) treatment, the novel combined technology that adds deep ablation to thermal ablation, leads to increased scarring improvement.<sup>130-137</sup>


Figure 12: (a) A representation of the types of acne scars and the mean depth of penetration of fractional lasers on the facial skin (based on both *ex vivo* and *in vivo* data). (b) A comparison of the dose and depth achieved with AFR. DeepFX, ActiveFX and Fraxel repair are fractional CO<sub>2</sub> lasers while the Palomar and Profractional are fractional Er:YAG lasers. (c) A comparative MTZ lesion reconstruction plots of three fractional lasers. The plotted shapes have an outer and inner diameter corresponding to the zone of coagulation and ablation. *k* represents the zone of necrosis.<sup>136</sup>







**b**



**c**



---

#### **(4) Sub-ablative devices**

Sub-ablative resurfacing employs fractional bipolar radiofrequency to create small epidermal wounds much wider in the dermis than epidermis (pyramidal shape).<sup>134</sup> The radiofrequency devices generate electric current using electromagnetic radiation in the range of 3 kHz to 300 MHz and produce heat through tissue impedance.<sup>138</sup> The impedance in the epidermis is higher than the dermis due to reduced water content, so the flow of electrical current is predominantly found in the dermis. The thermal damage in the deep dermal collagen stimulates the denaturation and contraction of collagen fibers, which brings the skin tightening effect.<sup>139</sup> Due to most of the thermal damage zones occurring in the dermis, this fractional RF device produces fewer side effects than fractional ablative lasers.

Additionally, this pattern of injury offers the benefit of the nonablative therapy with a mild degree of epidermal damage; the reports of adverse effects are similar across all nonablative laser studies included discomfort, transient erythema, and mild edema. It can be used safely in dark skin types due to the absence of chromophore-specific targets.<sup>140</sup> However, the combination of Fractional RF and fractional laser treatment increased PIH incidence to 6.5% .<sup>141</sup>


Microneedle RF comprises multiple parallel rows of microneedles or electrodes arranged in a bipolar array. Fractional RF devices include a handpiece applicator with a disposable tip. The different tips define the types of fractional RF. The superficial fractional RF is non-invasive RF technology that creates a close circuit in each pair of electrodes running parallelly on the

---

tips. Figure 13, identical to the bipolar current generated from each pair of microneedles in a microneedle RF.<sup>141</sup> The broad applications of fractional RF in dermatology include skin laxity, rhytides, cellulite, acne vulgaris, and scarring.<sup>133-142</sup> For example, Vermeer and his team used subablative fractional bipolar RF for treating patients with moderate to severe acne scars in 3-5 treatment sessions. Three months post-treatment, 50% were very satisfied, 50% of patients were satisfied with the overall improvement.<sup>142</sup>

**Figure 13 Superficial fractional RF tip.<sup>140</sup>**

## Sublative RF – The Technology



---

### **Characteristic of skin injuries after irradiation**

The Micro-ablative column stretches from the epidermis and upper dermis, with sparing of unaffected normal tissues. Zone of ablation is wide in the base of the wound extending from epidermis to upper dermis that narrow in the opening and MTZ with columns of altered collagen (MNZ), entire stratum corneum stays intact. The commonly used for treatment of atrophic acne scars are fractional erbium glass 1550/1540 nm laser for non-ablative fractional laser, and fractional 2940- nm Er:YAG laser and fractional 10,600-nm CO<sub>2</sub> laser for ablative fractional laser resurfacing (AFR).<sup>136</sup> The indication for this fractional technology are the following, chronic photodamage, skin laxity, rhytides, multiple types of scarring: acne scars, hypopigmented scars, and surgical scars and facial melasma.<sup>13</sup>

---

**Table 9: Comparison of AFR, Sub-ablative resurfacing and non-AFR after irradiation.<sup>140</sup>**

	<b>ABLATIVE FRACTIONAL LASER RESURFACING</b>	<b>SUB- ABLATIVE RESURFACING</b>	<b>NON- ABLATIVE FRACTIONAL LASER RESURFACING</b>
<b>Characteristic of skin injuries after irradiation</b>	<b>Micro-ablative column extending through epidermis and upper dermis, with sparing of unaffected normal tissues</b>	<b>Zone of ablation extending from epidermis to upper dermis that narrow in the opening and wide in the base of the wound</b>	<b>MTZ with columns of altered collagen (MNZ), entire stratum corneum remains intact.</b>

---

## **Fractional CO<sub>2</sub> laser and its application**

### **(1) Safety of fractional CO<sub>2</sub> laser**

The safety and adverse event of fractional CO<sub>2</sub> laser has been reported in many studies despite its high safety profile compared to the traditional ablative laser. Although some adverse events may be unavoidable, the patient will still experience erythema, edema, and PIH, but it can be resolved within one month after treatment.<sup>80-94</sup>

No machine before has been able to improve the skin appearance as evident as a CO<sub>2</sub> laser. Thus, most dermatologists regard the full-fill ablative tradition CO<sub>2</sub> laser as a gold standard for resurfacing.<sup>143</sup> Following Anderson and Parrish's discovery of the selective photothermolysis concept, the FrCO<sub>2</sub> laser was developed to deliver results similar to fully ablative resurfacing while sustaining an acceptable safety profile.<sup>136, 143</sup>

### **(2) Mechanism of Action**

Fractional carbon dioxide laser has combined the traditional carbon dioxide laser, which is 10,600 nm, with the fractional photo-thermolysis (FP) intervention technology. This way, the patient will experience lesser downtime such as transient erythema, crusting, and post-inflammatory pigmentation after each laser session, while still gaining the high efficacy of the traditional CO<sub>2</sub> laser. Nevertheless, some patients will still face the inflammation associated with laser treatment but in a lesser portion.<sup>92-104</sup> The target chromophore of FrCO<sub>2</sub> is principally tissue water, as same as CO<sub>2</sub>

---

laser, and the vital target structures are keratinocytes, collagen, and vessel. Skin ablation using a FrCO<sub>2</sub> typically ends in a classic quadruple zone response. First, from the position of laser contact, there is a zone of ablation (deep to the upper dermis) adjacent to the zone of necrosis (thin eschar layer), then the zone of coagulation and hyperthermia (as demonstrated in Figure 14) <sup>144</sup>.

A fluence of 5 J/cm<sup>2</sup> must be delivered to avoid excessive thermal damage, with a pulse duration of less than 1 ms, which is the thermal relaxation time of the skin.<sup>37-55</sup>


Hantash and colleagues demonstrated the column of thermal coagulation immediately after FrCO<sub>2</sub> laser treatment on ex vivo skin. Post-treatment, the ablative zone was replaced entirely with invaginating epidermal cells at 48 hours. The advantage of creating a microabrasion zone is a route for transepidermal drug delivery methods in a proper time (<48 hours).<sup>145</sup>

The collagen denaturation conventionally occurs at 66.8°C; after that, the collagen rapidly shrinks and contracts to one-third of its length. The tightening effect following FrCO<sub>2</sub> laser treatment is from collagen contraction and shrinkage. The collagenase, which degrades the fragmented collagen, initiates the wound healing process that first appears as a fast reconstruction of the epidermis by migrating cells from adnexal structures.<sup>146</sup> The period of dermal remodeling is up to 6 months following the treatment.<sup>14</sup> The dimensions of the microscopic ablation zone are dependable on the energy level employed. Ablation depth was significantly increased in a linear pattern with increasing energy levels. One study conducted in 2011 compared the morphologic dimension of the MTZs when using low (50mJ), medium

---

(100mJ), and high energy settings (300mJ). Outcomes illustrated that the MTZs reached the superficial dermis, mid-dermis, and deep dermis with low, medium, and high energy settings, respectively (as shown in Table 10). The dermal remodeling lasts for up to 4 weeks, which should be the minimum period between treatment sessions, and higher energies (300mJ) may provoke granuloma formation.<sup>85-100</sup>

**Figure 14 : Microscopic ablation zone (Abl. Depth = ablation depth, rae = radius of epidermal ablation, nz = necrosis zone, cz, = coagulation zone)<sup>144</sup>**



**Table 10 Morphometric dimension of MTZs in response to three different treatment protocols.<sup>144</sup>**

	<b>ABLATION DEPTH (<math>\mu</math>M)</b>	<b>ABLATION WIDTH EPIDERMAL (<math>\mu</math>M)</b>	<b>ABLATION WIDTH DERMAL (<math>\mu</math>M)</b>	<b>COAGULATION ZONE (<math>\mu</math>M)</b>	<b>NECROSIS ZONE (<math>\mu</math>M)</b>
<b>(A) Low setting</b>	<b>100 <math>\pm</math> 33. 6</b>	<b>224 <math>\pm</math> 36.5</b>	<b>4.9 <math>\pm</math> 16.3</b>	<b>68.9 <math>\pm</math> 15.7</b>	<b>1.6 <math>\pm</math> 3.6</b>
<b>(B) Medium setting</b>	<b>167 <math>\pm</math> 58. 9</b>	<b>260.7 <math>\pm</math> 60.2</b>	<b>110 <math>\pm</math> 74.5</b>	<b>50.5 <math>\pm</math> 14.7</b>	<b>6.7 <math>\pm</math> 4.4</b>
<b>(C) High setting</b>	<b>451 <math>\pm</math> 16 1.7</b>	<b>397.5 <math>\pm</math> 111. 5</b>	<b>166.6 <math>\pm</math> 41 .3</b>	<b>58.8 <math>\pm</math> 13.0</b>	<b>8.3 <math>\pm</math> 4.6</b>
<b>(A) vs. (B)</b>	<b><i>p</i> = 0.004</b>	<b><i>p</i> = 0.003</b>	<b><i>p</i> = 0.001</b>	<b><i>p</i> = 0.032</b>	<b><i>p</i> = 0.010</b>
<b>(B) vs. (C)</b>	<b><i>p</i> = 0.001</b>	<b><i>p</i> = 0.121</b>	<b><i>p</i> = 0.424</b>	<b><i>p</i> = 0.076</b>	<b><i>p</i> = 0.965</b>
<b>(A) vs. (C)</b>	<b><i>p</i> &lt; 0.001</b>	<b><i>p</i> = 0.001</b>	<b><i>p</i> &lt; 0.001</b>	<b><i>p</i> = 0.159</b>	<b><i>p</i> = 0.004</b>



---

### **(3) The Role of Fractional Carbon Dioxide Laser in Dermatology**

The clinical applications of FrCO<sub>2</sub> may divide into cosmetic and therapeutic applications.

#### **(A) Cosmetic Applications**

Photoaging and rhytides, periorbital resurfacing and blepharoplasty, laser-assisted drug delivery (triamcinolone, platelet-rich plasma, epidermal growth factor, tranexamic acid, and vitamin C), post-acne scars, keloid/hypertrophic scars, melasma, and striae utilize FrCO<sub>2</sub> laser for cosmetic purposes.<sup>30, 56, 147</sup>

#### **(B) Therapeutic Applications**

The application of FrCO<sub>2</sub> laser therapy in actinic keratosis, Bowen's disease, xanthelasma, seborrheic keratosis, warts, syringoma rhinophyma, and onychomycosis are employed for therapeutic purpose.<sup>80-92,148</sup>

#### **(C) Fractional Carbon Dioxide Laser for Acne Scars Treatment**

FrCO<sub>2</sub> has excellent efficacy for treating acne scars in many studies. However, after undergoing FrCO<sub>2</sub>, most patients anticipate the downtime, including white frosting, which may last for 5 to 10 minutes immediately following laser irradiation, accompanied by moderate to marked erythema and edema that ordinarily persist for 24 hours.<sup>24-33</sup> Typically, superficial crusting occurs, and re-epithelialization entirely disappears in 5 to 7 days, depending

---

on the laser's density and energy. PIH can be observed after the crusts slough off, generally around 1 or 2 weeks after the procedure.<sup>49-54</sup>

Although FrCO<sub>2</sub> provides excellent efficacy and fewer complications than non fractionated ablative laser treatment, yet adverse effects still occur (relatively uncommon).<sup>37, 149</sup> William M. Ramsdell has explained the complications of FrCO<sub>2</sub> including, infection (Staphylococcus, Pseudomonas, Klebsiella, and Enterobacter), koebner phenomenon, contact dermatitis, scarring, ectropion, dyschromia, prolonged erythema, acne eruption, and milia. Still, the possibility to acquire these complications may depend on the proper patient selection, pre-and post-operative care, and proper operative techniques.<sup>150</sup> In 2010, Manuskiatti and his colleagues found that FrCO<sub>2</sub> appeared to be effective and well-tolerated for treating atrophic acne scars in Asians, but mild PIH was found to be the side effect in 92% of the subjects.<sup>149</sup> A study evaluated the efficacy and safety of FrCO<sub>2</sub> in the treatment of acne scars, inferred that FrCO<sub>2</sub> promises to be an effective tool in the technologies for acne scar treatment, and the side effect found was post-treatment erythema.<sup>83</sup> Furthermore, Chan and his team have reported the prevalence and risk factors of PIH after practicing fractional resurfacing in Asians. The result showed that both the density and energy of the treatment determine the risk of PIH in dark-skinned patients.<sup>151</sup>

---

To conclude, much clinical success and safety have been published in utilizing a fractional laser to treat atrophic acne scar; a few side effects are still inevitable such as scarring, PIH, and persistent erythema.<sup>83, 140-151</sup> In addition, PIH is the most common adverse effect of post FrCO<sub>2</sub> treatment, especially in dark-skin individuals, including most of the Asian population.<sup>150</sup>

## **POSTOPERATIVE CARE**

There are four stages of dermal wound healing in Medium-depth and Deep resurfacing procedures: (1) Inflammation and Coagulation; (2) Re-epithelialization; (3) Fibroplasia and matrix formation; and (4) Collagen remodeling.<sup>36, 55</sup>

Pronounced edema following procedures may reduce the appearance of scars; this leads to a wrong judgment of an exaggerated improvement. Hence, counsel and advise the patient that continuous collagen remodeling will be for several months, facilitating clinical progress.<sup>80-88</sup> The healing period is directly proportional to the depth of the resurfacing procedure. Therefore, minimal downtime is sufficient for superficial resurfacing procedures as there is no dermal wound healing present.<sup>100-115</sup>

The severity of the erythema and desquamation is dependent on the techniques and wounding agent employed in the resurfacing procedure.<sup>56-60</sup>

During healing, regular washing with a mild cleanser, moisturizers, and sunscreens should suffice. Following resurfacing procedures, there is a longer

---

healing time, and more intensive postoperative care is essential.<sup>82-85</sup>

Occlusive dressings may be used during the first three postoperative days, which functions as a biologic dressing until peeling occurs. Then, the patient is directed to soak the areas four times daily with warm compresses and to apply an emollient after each soak and during the intervening periods as necessary. It is preferred to use 0.25% acetic acid solution (one tablespoon of white vinegar added to one pint of warm water) for the soaks because the mild acidity is physiologic for healing granulation tissue. It also has a mild debriding and antibacterial effects, especially against *Pseudomonas* spp. and other Gram-negative organisms. Occlusive emollients, such as petrolatum speed the process of re-epithelialization and reduce the tendency for delayed healing.<sup>89-98</sup> The emollients are additionally helpful in wound debridement and the prevention of crust formation and infection. Follow-up should be scheduled regularly to monitor the patient's postoperative course. At every visit, instructions for wound care are reviewed with the patient, and any questions are answered.<sup>120-132</sup>

Following the procedure, edema begins to appear almost immediately and progressively worsens during the first 48 hours. Aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), and oral steroids can be administered preoperatively and during the first 24 hours postoperatively to alleviate discomfort and reduce swelling.<sup>55-57</sup>

Gently debride the crusts with saline soaks and moistened cotton tips. The patient should be instructed to regularly apply an occlusive ointment to areas around the mouth, eyelids, and hairline that are not adequately covered by the

---

dressing.<sup>70-79</sup> Occlusive biosynthetic dressings have been shown to enhance collagen synthesis and hasten re-epithelialization in superficial wounds. They also minimize the amount of discomfort and prevent repeated soaks by the patient during the first few days after the procedure. Strict sun avoidance is critical for months.<sup>20-32</sup>


## **VITAMIN C**

### **1. Structure**

Vitamins are organic substances that maintain metabolic functioning in the body. Ascorbic acid (vitamin C, Figure 15) is the most plentiful and most typically water-soluble nonenzymic antioxidant in human tissue.<sup>152</sup> The chemical structure of ascorbic acid determines its physical and chemical properties. It is a weak, water-soluble, unstable organic acid which can be easily oxidized or destroyed by light, aerobic conditions (oxygen), high temperatures, alkali, copper, and heavy metals.<sup>153</sup> Vitamin C has several functions on the skin for example collagen synthesis, depigmentation and antioxidant activity.<sup>154</sup> Topical Vitamin C Serum may aid in the wound-healing process and minimize the posttreatment downtime.<sup>155</sup>

---

Figure 15. Chemical structure of ascorbic acid.



---

## 2. Metabolism

An insufficient amount of ascorbic acid is absorbed orally despite the high dose because an active transport mechanism limits the absorption of ascorbic acid in the intestine. Therefore, the bioavailability of ascorbic acid in the skin is insufficient following oral administration. Consequently, we require topical routes, exhibiting that the usage of local application aids in healing and better tissue reconstruction.<sup>27, 29</sup>

**Table 11: Vitamin C content of skin in comparison to other tissues<sup>155</sup>**

Tissue	Vitamin C Content (mg/100 g Wet Weight)
Adrenal glands	30–40
Pituitary glands	40–50
Liver	10–16
Spleen	10–15
Lungs	7
Kidneys	5–15
Heart muscle	5–15
Skeletal muscle	3–4
Brain	13–15
Skin-epidermis	6–64
Skin-dermis	3–13

---


### **3. USES OF VITAMIN C**

#### **a. Antioxidant Properties**

In biological systems, Vitamin C reduces both oxygens- and nitrogen-based free radicals and, therefore, acts as an antioxidant. It protects the skin by neutralizing reactive oxygen species (ROS) generated. A set of complex biochemical events occur in an orchestrated cascade to repair the damage if there is a skin injury.<sup>156, 157</sup> Ascorbic acid protects the skin by sequential donation of electrons by neutralizing free radicals since the oxidized forms of ascorbic acid are relatively unreactive. Therefore, the availability of ascorbic acid in the skin is reduced on repeated exposure to UV light. Ascorbic acid is often combined with another redox partner, such as vitamin E, in skincare formulations to slow oxidative degradation.<sup>155, 157</sup>



**Figure 16: Antioxidant Role of Vitamin C<sup>155</sup>**



## **b. Photoprotection**

Topical ascorbic acid can exert photoprotection against UVR due to its antioxidant and anti-inflammatory properties. A by-product of filaggrin: Trans-urocanic acid in the skin acts as a chromophore for photons of solar radiation leading to singlet oxygen formation, triggering a cascade of events that forms 'ROS'.<sup>157</sup> They can cause damage to nucleic acids, proteins, and cell membranes as they are highly toxic and unstable molecules. Furthermore, ROS triggers the signal transduction cascade inducing upregulation of factors, such as activation protein-1 (AP-1) and nuclear factor- $\kappa$ B, and downregulation of transforming growth factor- $\beta$  (TGF- $\beta$ ). As a result, Matrix Metalloproteinases (MMPs) are upregulated, which degrades collagen, reduces collagen production and, increases elastin accumulation.<sup>158,159</sup>

---

Clinical manifestations of this process are photoaging pigmentation, telangiectasias, coarse texture, deep wrinkles, and solar elastosis. Sunscreens are only partially effective in blocking free radicals produced on UV exposure. Vitamin C inhibits the activation of AP-1, which reduces MMP production and collagen damage.<sup>158</sup>

Cd1a-expressing Langerhans cells are reduced due to acute and chronic UV exposure. These are antigen-presenting cells in the epidermis, which are responsible for a protective immune response.<sup>155-160</sup> Vitamin C-containing topical solutions prevent the reduction of Cd1a-expressing Langerhans cells upon UV radiation. Therefore ward protection against UV-induced immunosuppression.<sup>155</sup>

UV-induced reactive oxygen species causes mutations on the p53 gene, affecting the repair of damaged deoxyribonucleic acid (DNA) and leading to programmed cell death (apoptosis).<sup>156</sup> UV-induced erythema and thymine dimer mutations add to photo carcinogenesis. 10% topical vitamin C reduces UVB-induced erythema by 52% and apoptotic sunburn cell formation by 40 - 60%. 19. Vitamin C solutions reduce UV-induced thymine dimers, thereby possibly diminishing the risk of photocarcinogenesis.<sup>27,155,160</sup>

### **c. Anti-aging**

Currently, medicine recognizes signs of aging by degenerative changes in the skin—for example, wrinkles, age spots, and skin flaccidity that

---

occur mainly due to oxyradical damage. 10% topical vitamin C reduced photoaged scores and improved wrinkling in a study.<sup>153-157</sup> Vitamin C regulates gene expression antioxidant enzymes, including those involved in DNA repair.<sup>15-159</sup> Ascorbic acid and its derivatives, such as 3-O-ethyl ascorbate or tetra-isopalmitoyl ascorbate, are used as anti-aging cosmetic products.<sup>160</sup>

#### **d. Anti-pigmentary**

Ascorbic acid also plays a role as anti-pigmentary agent. It interacts with copper ions at the active site of the tyrosinase enzyme thereby inhibiting the action of the enzyme. Tyrosinase is the main enzyme responsible for converting tyrosine into melanin, thereby decreasing melanin formation.<sup>28</sup> Tyrosinase catalyses the hydroxylation of tyrosine to dihydroxyphenylalanine (DOPA) and the oxidation of DOPA to its corresponding ortho-quinone.<sup>29</sup> Vitamin C prevents skin hyperpigmentation due to its ability to interfere with the action of tyrosinase, the rate-limiting enzyme in melanogenesis. The vitamin's ability to decrease the ortho-quinones generated by tyrosinase is plausibly responsible for melanin synthesis inhibition.<sup>30</sup> A clinical study examining the effect of a topical formulation containing 25% ascorbic acid and a chemical penetration enhancer reported a significant decrease in pigmentation caused by melasma after 16 weeks.<sup>31</sup>

---

#### **e. Wound Healing**

Fibroblasts require Ascorbic acid to synthesize stabilized collagen, which is fundamental in wound healing—ascorbic acid functions as a cofactor for various enzymes, such as lysyl hydroxylase and prolyl hydroxylase.<sup>154</sup> In the case of Vitamin C deficiency, unstable collagen yields a weak framework for repair, making wound healing difficult.<sup>155</sup> Ascorbic acid levels are usually low in older patients, contributing to slower and more difficult wound healing. Ascorbic acid prevents reduced proliferative capacity of in fibroblasts in older people.<sup>154-161</sup> In addition, vitamin C increases the proliferation and migration of dermal fibroblasts which is vital for efficient wound healing.<sup>162</sup> By stimulating regulatory hydroxylases, vitamin C also regulates the stabilization and activation of the hypoxia-inducible factor (HIF)-1, a metabolic sensor that guides the expression of hundreds of genes linked with cell survival and tissue remodelling, including collagenases. Finally, vitamin C synthesizes Glycosaminoglycan as part of extracellular matrix formation.<sup>154-161</sup>

#### **f. Topical Formulations**

L-ascorbic acid is a hydrophilic, unstable, and charged molecule; its penetration into the skin is inadequate due to the hydrophobic nature of the horny layer. Therefore, for optimal penetration of the epidermal barrier, aqueous formulations of ascorbic acid need to be at a pH that is below the pKa (4.2) of ascorbic acid itself.<sup>162</sup>

---

L-ascorbic acid is also combined with ferulic acid, thus stabilizing the molecule to reduce a pH lower than 3.5. The rate of ascorbic acid degradation is due to High pH or temperature, dissolved oxygen, and catalytic amounts of metal ions.<sup>27</sup> Thus, strategies such as encapsulation, low pH, oxygen-impermeable packaging, and the inclusion of electrolytes and other antioxidants are employed.<sup>155-160</sup> The more stable and easier derivatives to formulate are Ascorbyl 6-palmitate, tetra-isopalmitoyl ascorbate, magnesium ascorbyl phosphate, sodium ascorbyl phosphate, ascorbyl 2-glucoside, ascorbyl 2-phosphate-6-palmitate, and 3-O-ethyl ascorbate.<sup>153-161</sup> Ascorbyl 2-glucoside is one of the essential L-ascorbic acid derivatives because of its resistance to reduction and oxidation. It is also easily degraded by  $\alpha$ -glucosidase to release L-ascorbic acid and glucose.<sup>155</sup> Patients who apply topical ascorbyl 6-palmitate to burns caused by UV radiation obtained a reduced redness by 50%, proposing that the derivative acts as an antioxidant and anti-inflammatory agent.<sup>160-162</sup> Ascorbyl phosphate is a free radical scavenger, a photoprotective agent that increases collagen production levels. Ascorbyl 2-phosphate 6-palmitate can penetrate the skin and be converted to ascorbic acid after delivery, showing skin absorption limited by topical application.<sup>159-162</sup>


#### **g. Safety**

Ascorbic acid is safe at high usage levels for long periods due to its solubility in water. No adverse effects have been observed in any well-controlled studies reviewed that indicated daily intakes of more than

---

100 times the U.S. recommended daily amount of vitamin. Any excess consumption tends to excrete from the body in the urine.<sup>155</sup> This is the reason why concentrations of ascorbic acid and other water-soluble vitamins can rarely accumulate to toxic levels.<sup>156-159</sup>

**Figure 17: Delivery of Nutrients to the Skin. SVCT1 and SVCT2 are the transporter proteins of Vitamin C. Red arrow indicate nutritional flow from blood vessels in the dermis to the epidermal layer. Nutrients delivered by topical application have to penetrate stratum corneum.<sup>155</sup>**



# **MATERIALS AND METHODS**



---

## **MATERIALS AND METHODS**

### **(1)Source of data:**

This study was conducted in outpatient clinic of Dermatology, Venereology and Leprosy in R L Jalappa Hospital and Research Centre attached to Sri Devaraj Urs Medical College, Tamaka, Kolar from January 2020 to July 2021.

### **(2)Study Design:**

Prospective Study

### **(3)Sample size calculation:**

Sample Size was estimated based on excellent and good results seen in acne scars patients by treatment with Fractional CO<sub>2</sub> laser as monotherapy<sup>12</sup>. The observed proportions as 68.3% expecting an improvement of 25% in excellent and good results with Fractional CO<sub>2</sub> Laser in combination with Topical Vitamin C Serum with 95% confidence and  $\alpha$  error of 5%, estimated sample size per group was 38.



---

## Formula

$$H_0 : P_1 = P_2; \quad H_a : P_1 \neq P_2$$

$$n = \frac{\left\{ Z_{1-\frac{\alpha}{2}} \sqrt{2 \bar{P} (1 - \bar{P})} + Z_{1-\beta} \sqrt{P_1 (1 - P_1) + P_2 (1 - P_2)} \right\}^2}{(P_1 - P_2)^2}$$

Where,

$$\bar{P} = \frac{P_1 + P_2}{2}$$

$P_1$  : Proportion in the first group

$P_2$  : Proportion in the second group

$\alpha$  : Significance level

$1-\beta$  : Power

Proportion in group I = 0.683

Proportion in group II = 0.933

Risk difference = -0.25

Power(%) = 80

Alpha Error(%) = 5

Side = 2

Required sample size for each arm = **38**

---

#### **(4) Statistical Analysis:**

Data was entered into Microsoft excel data sheet and was analyzed using SPSS 22 version software. Categorical data was represented in the form of Frequencies and proportions. **Chi-square test or Fischer's exact test** (for 2x2 tables only) was used as test of significance for qualitative data.

Continuous data was represented as mean and standard deviation.

**Independent t test** was used as test of significance to identify the mean difference between two quantitative variables.

**Graphical representation of data:** MS Excel and MS word was used to obtain various types of graphs. **P value** (Probability that the result is true) of  $<0.05$  was considered as statistically significant after assuming all the rules of statistical tests.

**Statistical software:** MS Excel, SPSS version 22 (IBM SPSS Statistics, Somers NY, USA) was used to analyze data

---

## **(5) Method of collection of data (including sampling procedure)**

### **(1)Inclusion criteria:**

- 1) Age group between 18 and 40 years
- 2) Moderate to Severe acne scars (as per Goodman and Baron's acne scar grading scale)

### **(2)Exclusion criteria:**

- 1) Patients with a predisposition to keloid, active infection, herpes, HIV, HBV infection.
- 2) Patients on oral isotretinoin use in preceding 6 months.
- 3) Patients with diabetes mellitus, collagen vascular disease.
- 4) Patients with h/o ablative or nonablative laser skin resurfacing within the preceding 12 months.
- 5) Pregnant or lactating women
- 6) Patients with bleeding diathesis
- 7) Patients with unreasonably high expectations were excluded from this study. But we will provide them with all treatment options and their success rates and use multiple modalities if necessary.

---

**(3) Sample size:**

Sample size per group is 38.

38 participants will be treated with Fractional CO<sub>2</sub> Laser Monotherapy and other 38 participants will be treated with Fractional CO<sub>2</sub> Laser in combination with Topical Vitamin C Serum.

**Methodology:**

All patients satisfying the inclusion criteria will be divided into two groups as follows

GROUP 1- participants will be treated with Fractional CO<sub>2</sub> Laser

GROUP 2- participants will be treated with Fractional CO<sub>2</sub> Laser in combination with Topical Vitamin C Serum within 2 minutes immediately after laser and daily for 4 months.

All participants were treated with Fractional CO<sub>2</sub> laser at an interval of 4 weeks for 3 sessions. A topical anaesthetic, containing a mixture of lidocaine-2.5% w/w + prilocaine-2.5% w/w in a cream base will be applied for 1 hour on the treatment area. After satisfactory anaesthesia was achieved, the treatment area will be cleaned with a mild cleanser followed by 70% ethanol solution. Eyes were protected with eye shields. Fractional CO<sub>2</sub> laser treatment was then delivered to each atrophic scar present. Ice pack was applied immediately.

---

Participants underwent serial photography of the lesions at baseline, 1 month, 2 months, 3 months and follow up after 4 months from the first treatment session with same assessment scaling and questionnaire. Lighting and positioning was kept identical for all serial photographs. Each participant was instructed to evaluate his/her overall satisfaction with the treatment at end of 1<sup>st</sup> and 4<sup>th</sup> month of the treatment using a quartile grading system which defined 0 as unsatisfied, 1 as slightly satisfied, 2 as satisfied, or 3 as very satisfied. The visual analog scale (scoring from 0 to 10) was used to record adverse events (erythema and edema) as perceived by participants on days 0, 2, 4, 6, 8, 15 and 30 after each treatment session.

Finally, the occurrence of other possible side adverse events including secondary infection, acneiform eruption, dyschromia and new scar formation was assessed. The final assessment was made subjectively by a single observer at the last follow-up visit, and a quartile grading scale was used to assess the response objectively. A score of 0, 1, 2 and 3 will be given if the response was <25%, 25-50%, 51-75% and >75%, respectively. Sunscreen with spf 50 was prescribed for daily use in the morning and afternoon. Counselling was done for all patients.

# RESULTS



---

## **RESULTS**

The study included 76 participants, Group1 had 38 participants treated with Fractional CO<sub>2</sub> Laser, and Group 2 had 38 participants treated with Fractional CO<sub>2</sub> Laser in combination with Topical Vitamin C Serum within 2 minutes immediately after laser daily for four months.

In both groups, a maximum number of patients were in age groups of between 21-25 years, followed by 26-30 years. Table 12 depicts the distribution of patients according to the age group between Group 1 and Group 2. No statistically significant difference ( $p=0.964$ ) was found between the groups with respect to age. (Graph 1).

Females in Group 1 were 21/38 (55.3%), and in Group 2 were 20/38 52.6%) whereas there were 17/38 (44.7%) of males in Group 1 and 18/38 (47.4%) of males in Group 1. There was no statistically significant difference ( $p=0.818$ ) found between groups with respect to sex. (Table 13) (Graph 2) (Graph 3).

27/38 (71.1%) and 23/38 (60.5%) of patients were unmarried in Group 1 and Group 2, respectively. There was no statistically significant difference ( $p=0.818$ ) found between groups with respect to marital status. (Table 14) (Graph 4). There was also no statistically significant difference ( $p=0.560$ ) found between groups with respect to occupation. (Table 15) (Graph 5).

---

Table 16 and Graph 6 Illustrate that >65% of patients were Fitzpatrick skin type IV in Group 1 as well as in Group 2 while <8% of patients were Fitzpatrick skin type II in both the groups and rest had Fitzpatrick skin type III. However, There was also no statistically significant difference ( $p=0.744$ ) found between groups with respect to Fitzpatrick skin types.

With a P-value of 0.788, there was no statistically significant difference found between groups with respect to grading of the scar. Although 28/38 (73.7%) and 30/38 (78.9%) of patients had Grade 4 scars in Group 1 and Group 2, respectively, and 10/38 (26.3%) and 8/38 (21.1%) of patients had Grade 3 scars in Group 1 and Group 2, respectively. (Table 17) (Graph 7).

A statistically significant difference ( $p<0.001$ ) was found between the groups with respect to improvement in the appearance of scars after six months. 16/38 (42.1%) and 20/38 (52.6%) of Group 2 patients had >75% and 50-75% of improvement compared to Group 1 where 8/38 (21.1%) and 16/38 (31.6%) of patients had >75%, and 50-75% of improvement was seen. (Table 18) (Graph 8).



---

As far as patient satisfaction is concerned, >80% of patients were either satisfied or very satisfied in both groups. Therefore, there was no statistically significant difference ( $p=0.192$ ) found between the groups with respect to patient satisfaction. (Table 19) (Graph 9).

Table 20 and Graph 10 show no statistically significant difference between the two groups with respect to edema on Day 1 at the first session, second session, and third session following CO<sub>2</sub> Laser therapy. However, there was a statistically significant difference between the two groups regarding edema on Day 7 at the first session, second session, and the third session of CO<sub>2</sub> Laser therapy.

Table 21 and Graph 11 represent no statistically significant difference found between the two groups with respect to erythema on Day 1 at the first session. Nevertheless, following the second session and third session of CO<sub>2</sub> Laser therapy, we found a statistically significant difference ( $p<0.001$ ) between the two groups regarding erythema on Day 1. Furthermore, during treatment, we observed a statistically significant difference ( $p<0.001$ ) between the two groups with respect to erythema on Day 7 at the first session, second session, and third session after CO<sub>2</sub> Laser treatment.

---

Finally, 7/38 (18.4%) of patients in Group 1 developed Post Inflammatory Hyperpigmentation (PIH), but it was resolved within three months after receiving treatment for PIH. 2 patients from Group 1 and 1 patient from Group 2 developed Acneiform eruption, which also resolved on treatment. With a P-value of 0.016, there was a statistically significant difference found between groups with respect to side effects, as depicted in Table 22 and Graph 12.

---

**FIGURE 18 : GROUP 1- Case 1 Front Face Profile**




**BASELINE**

**THREE MONTHS  
POST TREATMENT**

**SIX MONTHS  
POST TREATMENT**

**FIGURE 19 : GROUP 1- Case 1 Right Face Profile**



**FIGURE 20 : GROUP 1- Case 1 Left Face Profile**




**FIGURE 21 : GROUP 1- Case 2 Front Face Profile**



---

**FIGURE 23 : GROUP 1- Case 2 Right Face Profile**



**FIGURE 22 : GROUP 1- Case 2 Left Face Profile**




**FIGURE 23: GROUP 2- Case 1 Front Face Profile**





**FIGURE 24: GROUP 2- Case 1 Right Face Profile**



**FIGURE 25: GROUP 2- Case 1 Left Face Profile**





**FIGURE 26: GROUP 2- Case 2 Front Face Profile**



**BASELINE**

**THREE MONTHS  
POST TREATMENT**

**SIX MONTHS  
POST TREATMENT**

**FIGURE 27: GROUP 2- Case 2 Right Face Profile**



**BASELINE**

**THREE MONTHS  
POST TREATMENT**

**SIX MONTHS  
POST TREATMENT**

**FIGURE 28: GROUP 2- Case 2 Left Face Profile**



**BASELINE**

**THREE MONTHS  
POST TREATMENT**


**SIX MONTHS  
POST TREATMENT**

---

**Table 12: Distribution of subjects according to age group between the groups.**

	<b>Group 1</b>	<b>Group 2</b>
<b>&lt;20yrs</b>	<b>5</b>	<b>5</b>
	<b>13.2%</b>	<b>13.2%</b>
<b>21-25yrs</b>	<b>17</b>	<b>15</b>
	<b>44.7%</b>	<b>39.5%</b>
<b>26-30yrs</b>	<b>12</b>	<b>14</b>
	<b>31.6%</b>	<b>36.8%</b>
<b>&gt;30yrs</b>	<b>4</b>	<b>4</b>
	<b>10.5%</b>	<b>10.5%</b>
<b>Total</b>	<b>38</b>	<b>38</b>
	<b>100.0%</b>	<b>100.0%</b>

**Graph 1 : Distribution of subjects according to age group between the groups.**




**Table 13: Distribution of subjects according to gender between the groups.**


	Group 1	Group 2
<b>Female</b>	<b>21</b>	<b>20</b>
	<b>55.3%</b>	<b>52.6%</b>
<b>Male</b>	<b>17</b>	<b>18</b>
	<b>44.7%</b>	<b>47.4%</b>
<b>Total</b>	<b>38</b>	<b>38</b>
	<b>100.0%</b>	<b>100.0%</b>

---

**Graph 2: Distribution of subjects according to gender in group 1**




**Graph 3: Distribution of subjects according to gender in group 2**



**Table 14: Distribution of subjects according to marital status between the groups.**

	Group 1	Group 2
<b>MARRIED</b>	<b>11</b>	<b>15</b>
	<b>28.9%</b>	<b>39.5%</b>
<b>UNMARRIED</b>	<b>27</b>	<b>23</b>
	<b>71.1%</b>	<b>60.5%</b>
<b>Total</b>	<b>38</b>	<b>38</b>
	<b>100.0%</b>	<b>100.0%</b>

**Graph 4: Patient Distribution according to marital status between the groups.**




---

**Table 15:- Distribution of subjects according to occupation between the groups.**

	<b>Group 1</b>	<b>Group 2</b>
<b>Professionals</b>	<b>19</b>	<b>18</b>
	<b>50.0%</b>	<b>47.4%</b>
<b>Skilled worker</b>	<b>3</b>	<b>1</b>
	<b>7.9%</b>	<b>2.6%</b>
<b>Unskilled worker</b>	<b>4</b>	<b>5</b>
	<b>10.5%</b>	<b>13.2%</b>
<b>Housewife</b>	<b>1</b>	<b>4</b>
	<b>2.6%</b>	<b>10.5%</b>
<b>Student</b>	<b>11</b>	<b>10</b>
	<b>28.9%</b>	<b>26.3%</b>

**Graph 5: Patient Distribution according to occupation between the groups.**




**Table 16:- Patient Distribution according to fitzpatrick skin type between the groups**

	Group 1	Group 2
II	3	2
	7.9%	5.3%
III	10	8
	26.3%	21.1%
IV	25	28
	65.8%	73.7%




**Graph 6:- Patient Distribution according to fitzpatrick skin type between the groups.**



**Table 17:- Distribution of subjects according to grading of scar between the groups.**

	Group 1	Group 2
3	10	8
	26.3%	21.1%
4	28	30
	73.7%	78.9%
Total	38	38
	100.0%	100.0%

**Graph 7: Patient Distribution according to grading of scar between the groups.**




---

**Table 18:- Distribution of subjects according to improvement after 6months between the groups.**

	<b>Group 1</b>	<b>Group 2</b>
<b>&lt;25%</b>	<b>4</b>	<b>1</b>
	<b>10.5%</b>	<b>2.6%</b>
<b>25-50%</b>	<b>14</b>	<b>1</b>
	<b>36.8%</b>	<b>2.6%</b>
<b>50-75%</b>	<b>12</b>	<b>20</b>
	<b>31.6%</b>	<b>52.6%</b>
<b>&gt;75%</b>	<b>8</b>	<b>16</b>
	<b>21.1%</b>	<b>42.1%</b>

**Graph 8:- Patient Distribution according to improvement in appearance of scars after 6 months**




---

**Table 19:- Distribution of subjects according to patient's satisfaction between the groups.**

	<b>Group 1</b>	<b>Group 2</b>
<b>Unsatisfied</b>	<b>3</b>	<b>0</b>
	<b>7.9%</b>	<b>.0%</b>
<b>Slightly satisfied</b>	<b>4</b>	<b>3</b>
	<b>10.5%</b>	<b>7.9%</b>
<b>Satisfied</b>	<b>15</b>	<b>12</b>
	<b>39.5%</b>	<b>31.6%</b>
<b>Very satisfied</b>	<b>16</b>	<b>23</b>
	<b>42.1%</b>	<b>60.5%</b>

**Graph 9: Patient Distribution according to patient’s satisfaction between the groups.**




---

**Table 20: Comparison of edema on Day 1 and Day 7 at various session between two groups between the groups.**

	Group 1		Group 2		P value
	Mean	SD	Mean	SD	
<b>1<sup>st</sup> Session Day 1</b>	<b>4.53</b>	<b>1.87</b>	<b>4.08</b>	<b>1.89</b>	<b>0.304</b>
<b>2<sup>nd</sup> Session Day 1</b>	<b>4.18</b>	<b>1.61</b>	<b>3.66</b>	<b>1.55</b>	<b>0.150</b>
<b>3<sup>rd</sup> Session Day 1</b>	<b>4.03</b>	<b>1.67</b>	<b>3.45</b>	<b>1.39</b>	<b>0.104</b>
<b>1<sup>st</sup> Session Day 7</b>	<b>.68</b>	<b>.99</b>	<b>.16</b>	<b>.37</b>	<b>0.004</b>
<b>2<sup>nd</sup> Session Day 7</b>	<b>.29</b>	<b>.52</b>	<b>.03</b>	<b>.16</b>	<b>0.004</b>
<b>3<sup>rd</sup> Session Day 7</b>	<b>.39</b>	<b>.82</b>	<b>.11</b>	<b>.31</b>	<b>0.046</b>


---

**Graph 10:- Comparison of edema on Day 1 at various session between two groups between the groups**





**Graph 11: Graph showing Comparison of edema on Day 7 at various session between two groups between the groups.**




---


**Table 21: Comparison of erythema on Day 1 and Day 7 at various session between two groups between the groups.**

	Group 1		Group 2		P value
	Mean	SD	Mean	SD	
<b>1<sup>st</sup> Session Day 1</b>	<b>5.74</b>	<b>1.83</b>	<b>5.08</b>	<b>1.94</b>	<b>0.132</b>
<b>2<sup>nd</sup> Session Day 1</b>	<b>5.11</b>	<b>1.59</b>	<b>3.97</b>	<b>1.55</b>	<b>&lt;0.001</b>
<b>3<sup>rd</sup> Session Day 1</b>	<b>4.92</b>	<b>1.62</b>	<b>3.63</b>	<b>1.46</b>	<b>&lt;0.001</b>
<b>1<sup>st</sup> Session Day 7</b>	<b>1.50</b>	<b>1.18</b>	<b>.66</b>	<b>.75</b>	<b>&lt;0.001</b>
<b>2<sup>nd</sup> Session Day 7</b>	<b>1.03</b>	<b>.85</b>	<b>.18</b>	<b>.46</b>	<b>&lt;0.001</b>
<b>3<sup>rd</sup> Session Day 7</b>	<b>.76</b>	<b>.71</b>	<b>.05</b>	<b>.23</b>	<b>&lt;0.001</b>

**Graph 12: Comparison of erythema on Day 1 at various session between two groups between the groups.**




**Graph 13: Graph showing Comparison of erythema on Day 7 at various session between two groups between the groups.**



**Table 22: Distribution of subjects according to side effects between the groups**

	Group 1	Group 2
<b>NIL</b>	<b>29</b>	<b>37</b>
	<b>76.3%</b>	<b>97.4%</b>
<b>PIH</b>	<b>7</b>	<b>0</b>
	<b>18.4%</b>	<b>.0%</b>
<b>Acneiform eruption</b>	<b>2</b>	<b>1</b>
	<b>5.3%</b>	<b>2.6%</b>

**Graph 14:- Patient Distribution according to Side Effects between the groups.**



# DISCUSSION



---

## DISCUSSION

Laser devices have the advantage of controlling the tissue depth penetration in an organ. The application of fractional ablative lasers to deliver bioactive agents to a patient through tunnels of intended depth into cutaneous tissue has vast clinical implications. This technology programs fractional lasers to intrude the skin's barrier properties, generating deep channels to allow local delivery of cellular agents through the disrupted barrier.<sup>156,157</sup>

### **Age distribution:**

Many studies published that patients in the most prevalent age group seeking treatment for acne scars were between 21-25 years, followed by 26-30 years. A study conducted by T. Pooja and her team observed that 61.6% of subjects were in the 18–24 years age group followed by 31.6% of subjects were in 25–31 years age group.<sup>92</sup> 40% and 30% of acne scar patients in a clinical trial conducted in Punjab, India belonged to age groups between 21-25 years and 26-30 years, respectively.<sup>83</sup> In our study, 42.1.% of subjects were between 20-25 years, followed by 34.2% of patients between 26-30 years. This is in agreement with Al Taweel AI Study and Tenna S Study, where the maximum prevalence of acne scars was witnessed in the age group 20- 30 years.<sup>110,124</sup>

---

### **Gender Distribution:**

In our study, 55.3% and 52.6% of female patients were present in Group 1 and Group 2, respectively. At the same time, 44.7% and 47.4% of male patients were in Group 1 and Group 2, respectively. Concurrent to this study conducted by Majid I and Imran S saw 35 female and 25 male patients receive treatment for atrophic acne scars in Jammu & Kashmir, India.<sup>12</sup> Similarly, another study in Cairo, Egypt, commented that 16 female and 14 male patients sought treatment for atrophic acne scar.<sup>99</sup>

### **Fitzpatrick Skin Type**

The majority of studies observed that patients looking for acne scars treatment had Fitzpatrick Skin Type III and Type IV. In a Korean Study, all patients belonged to either Fitzpatrick Skin Type III or Type IV.<sup>94</sup> Our study showed 26.3% and 21.1% patients with Fitzpatrick Skin Type IV in Group 1 and Group 2, respectively. There were 65.8% and 73.7% patients with Fitzpatrick Skin Type III in Group 1 and Group 2, respectively. In agreement with our study, Wanitphakdeedecha R and his colleagues observed that 11.11% and 86.11% of patients were Fitzpatrick Skin Type III and Type IV, respectively. They also found out that the majority of their patients developed transient PIH. Most Indians are Fitzpatrick Skin Type III and IV and are, therefore, prone to Hyperpigmentation post-procedure. It is valuable to use a Depigmenting agent post-procedure for acne scarring.<sup>102</sup> Pigmented scars in Indian skin, which belong to Fitzpatrick type 3–5, are one of the most striking features. Dark skin type has a huge inclination to acne scarring and is frequently complicated by persistent erythema or pigmentation at the base. Initial erythema is succeeded by the purplish base, which may later pigment.<sup>103</sup>



---

### **Grading of Acne Scar**

Acne scars respond poorly to medical treatment, and achieving an acceptable level of patient satisfaction remains a challenge. On pretreatment assessment by Goodman and Baron qualitative grading of acne scars, we found 10/38 (26.3%) of patients had grade 3, and 28/38 (73.7%) of patients had grade 4 scoring in Group 1, whereas 8/38 (21.1%) and 30/38 (78.9%) of patients had grade 3 and 4 scoring in Group 1, respectively. Contrary to our study, Neinaa and their team conducted research in which more patients had Grade 3 than Grade 4 acne scars (48.8% of patients had Grade 3, and 36.6% had Grade 4 Acne scars).<sup>97</sup> Mild-to-moderate scars involving epidermis and papillary dermis respond to resurfacing laser or other technologies, whereas the deep scars involving reticular dermis require more aggressive or combination modalities.<sup>66</sup> High-grade acne leads to a high degree of inflammation, as seen with papulonodular and cystic acne; a dermal insult to tissue metalloproteinases is more long-lasting and results in a decrease of tissue leading to atrophic scars.<sup>8</sup>

### **Post Treatment**

#### **(1) Appearance of scar after six months**

Most clinical trials have documented CO2 Laser efficacious in treating facial atrophic acne scars. A study on the Indian population receiving CO2 Laser as monotherapy reported 68.3% Good or Excellent Improvement.<sup>12</sup> In our study, Group 2 patients showed 52.6% Good and 42.1% Excellent improvement, whereas Group 1 patients had 31.6% Good and 21.1% Excellent improvement in the appearance of acne scars after six months.

---

A statistically significant difference ( $p<0.001$ ) was found between the groups with respect to improvement in the appearance of scars after six months.

This is in accordance with a study by Waibel JS and his team, which reported more rapid wound healing post-fractional ablative laser. They found out that Elevated bFGF could be involved in Vitamin C, E, and Ferulic acid-induced rapid wound healing.<sup>157</sup> However, this was incompatible with a study by Chawla S and her colleagues concluded that overall results were better with micro-needling and PRP. Vitamin C combined with micro-needling also showed improvement in firmness and smoothness of skin and post-inflammatory hyper-pigmentation. Excellent response was seen in 18.5% of patients with PRP compared to 7% of patients who received vitamin C.<sup>163</sup> Vitamin C's flux and skin deposition across microdermabrasion-treated skin was approximately 20-fold higher than that across patients intact skin.<sup>21</sup> In our study, >80% of patients were either satisfied or very satisfied in both groups. Therefore, there was no statistically significant difference ( $p=0.192$ ) found between the groups with respect to patient satisfaction.

## **(2) Post Irradiation Edema and Erythema**

The Mean $\pm$ SD edema was  $4.53\pm1.87$  in Group 1 on Day 1 after the first session, while in Group 2, it was  $4.08\pm1.89$ . Moreover, there was no statistically significant difference between the two groups with respect to edema on Day 1 after the first session, second session, and third session of CO<sub>2</sub> Laser therapy. However, Mean $\pm$ SD Edema was  $0.6 \pm 0.99$  in Group 1, while in Group 2, it was  $0.16\pm 0.37$ . There was a statistically significant difference ( $p<0.001$ ) between the groups on Day 7 after the first session, second session, and third session of CO<sub>2</sub> Laser therapy.

---

Consistent with this study, a study reported no significant reduction of bFGF expression five days posttreatment laser therapy with topical Vitamin C, E, and Ferulic acid serum compared to the control group.<sup>157</sup>

Vitamin C, E, and Ferulic acid treatment can block laser treatment-induced down-regulation of bFGF in the skin. bFGF is a glycoprotein, which is widely used in treating wounds and ulcers. Furthermore, bFGF receptor blocker and anti-bFGF antibody significantly decrease proliferative activity in adult and fetal skin fibroblasts, suggesting that bFGF plays a critical role in wound healing.<sup>157</sup>

No statistically significant difference was found between the two groups with respect to erythema on Day 1 at the first session. Nevertheless, following the second and third sessions of CO<sub>2</sub> Laser therapy, we found a statistically significant difference between Day 1. Furthermore, during treatment, we observed a statistically significant difference between the groups on Day 7 after the first session, second session, and third session of CO<sub>2</sub> Laser treatment. It has been observed that Vitamin C enhances the gene expressions of protein coding genes CollA1, TGF- $\beta$ 1, TGF- $\beta$ 3, MMP-1, MMP-13, and bFGF, which are involved in wound-healing processes.<sup>157</sup> This insight may help explain the exhibited clinical trends of decreasing postoperative downtime. Thus, Vitamin C treatment may improve wound healing by blocking the downregulation of bFGF by laser treatment.<sup>161</sup> However, the detailed signaling pathway involved in the upregulation of bFGF by Vitamin C therapy needs to be further investigated.

---

### **(3) Adverse Effects**

Lastly, patients in both groups developed transient adverse effects. For Example- 7/38 (18.4%) of patients in Group 1 developed PIH. In addition to that, 2/38 patients from Group 1 and only 1/38 patients from Group 2 developed Acneiform eruption. With a P-value of 0.016, a statistically significant difference was found between groups with respect to side effects, as depicted in Table 22 and Graph 14. Although ascorbic acid has no UV absorption spectra in the UVA (320 to 400 nm) or UVB (290 to 320 nm) range, topical ascorbic acid can exert photoprotection against UVR because of its antioxidant and anti-inflammatory characteristics. Ascorbic acid also plays a role as an anti-pigmentary agent.<sup>155</sup> It interacts with copper ions at the active site of the tyrosinase enzyme, thereby hindering the enzyme's activity. Tyrosinase is the primary enzyme liable for converting tyrosine into melanin, thereby limiting melanin formation.<sup>157</sup>

# CONCLUSION

---



---

## CONCLUSION

Fractional CO<sub>2</sub> Laser as Monotherapy and Fractional CO<sub>2</sub> Laser in combination with Topical Vitamin C Serum is effective and safe in treating Atrophic Facial Acne Scars. There are minimal transient Post Laser adverse effects of Fractional CO<sub>2</sub> Laser alone, but they can be avoided when combined with Topical Vitamin C serum.

Fractional photothermolysis grants the highest degree of scar amelioration. However, it is essential to realize that a typical Indian patient is prone to PIH following an ablative Laser. Therefore, our results contribute to a potentially new understanding of topical Vitamin C serum in preventing PIH and wound-healing following ablative laser surgery. Furthermore, our results exhibited shorter durations of major side effects after combined therapy.

The erythema and edema post laser therapy are significantly reduced when fractional co<sub>2</sub> laser therapy is combined with topical vitamin c serum, and thus, the downtime is also lessened.

The current study infers that applying topical Vitamin C serum after ablative fractional CO<sub>2</sub> Laser improves clinical outcomes in patients with atrophic acne scarring and hastens recovery of laser-damaged skin.

# SUMMARY

A decorative graphic consisting of a thick horizontal line and a thick vertical line intersecting at the right end of the horizontal line, positioned below the word 'SUMMARY'.

---

## SUMMARY

The study was a double-blinded randomized trial among 76 subjects; 38 in Fractional CO<sub>2</sub> laser monotherapy (Group1) and 38 in the Fractional CO<sub>2</sub> Laser in combination with Vitamin C serum within 2 minutes immediately after Laser and daily for four months (Group 2). Patients with facial atrophic acne scar belonging to both sexes, within an age group of 18 -40 years, with moderate to severe scar, and willing to undergo treatment and follow up were included in the study.

Participants underwent serial photography of the lesions at baseline, 1 month, 2 months, 3 months, and 4 months from the first treatment session. The visual analog scale (scoring from 0 to 10) was used to record adverse events (erythema and edema) as perceived by participants. The final assessment was made subjectively by a single observer at the last follow-up visit, and a quartile grading scale was used to assess the response objectively. P-value of <0.05 was considered statistically significant after assuming all the rules of statistical tests.

A statistically significant difference ( $p < 0.001$ ) was found between the groups with respect to improvement in the appearance of scars after six months. 42.1% and 52.6% of Group 2 patients had >75% and 50-75% of improvement. 21.1% and 31.6% of patients in Group 1 had >75%, and 50-75% of improvement. >80% of patients were either satisfied or very satisfied in both groups. A statistically significant difference ( $p < 0.001$ ) was found between the groups regarding erythema and edema on Day 7 after the CO<sub>2</sub> laser therapy session. With a P-value of 0.016, a statistically significant difference was observed between the groups concerning side effects. The combination of using an ablative fractional CO<sub>2</sub> laser and Vitamin C serum in the treatment of atrophic scars has a synergistic effect on their inherent properties in up-regulating new collagen synthesis to improve atrophic scars. Erythema, edema, and post-laser downtime are significantly reduced, with diminished risk of adverse effects.



# **BIBLIOGRAPHY**

---



---

## BIBLIOGRAPHY

1. Gollnick HP, Zouboulis CC, Akamatsu H, Kurokawa I, Schulte A. Pathogenesis and pathogenesis-related treatment of acne. *J Dermatol* 1991;18:489-99.
2. Leyden JJ. New understanding of the pathogenesis of acne. *J Am Acad Dermatol* 1995;32:515-25.
3. Bhate K, Williams HC. Epidemiology of acne vulgaris. *Br J Dermatol*. 2013;168:474-85.
4. Tan JK, Tang J, Fung K, et al. Development and validation of a comprehensive acne severity scale. *J Cutan Med Surg*. 2007; 11:211-6.
5. Martin AR, Lookingbill DP, Botek A, et al. Health-related quality of life among patients with facial acne: assessment of a new acne-specific questionnaire. *Clin Exp Dermatol*. 2001; 26:380-5.
6. Rapp SR, Feldman SR, Graham G, et al. The Acne Quality of Life Index (Acne-QOLI): development and validation of a brief instrument. *Am J Clin Dermatol*. 2006;7:185-92.
7. Fife D. Practical evaluation and management of atrophic acne scars: tips for the general dermatologist. *J Clin Aesthet Dermatol*. 2011;4:50–57.
8. Connolly D, Vu HL, Mariwalla K, Saedi N. Acne Scarring—Pathogenesis, Evaluation, and Treatment Options. *The Journal of Clinical and Aesthetic Dermatology*. 2017;10(9):12-23.
9. Werschler WP, Herdener RS, Ross VE, Zimmerman E. Critical considerations on optimizing topical corticosteroid therapy. *J Clin Aesthet Dermatol*. 2015;8(8 Suppl):S2-8.

- 
10. Rivera AE. Acne scarring: a review and current treatment modalities. *J Am Acad Dermatol.* 2008;59(4):659–76.
  11. Nirmal B, Pai SB, Sripathi H, Rao R, Prabhu S, Kudur MH, Nayak SUK. Efficacy and safety of erbium-doped yttrium aluminium garnet fractional resurfacing laser for treatment of facial acne scars. *Indian J Dermatol Venereol Leprol.* 2013;79(2):193–8.
  12. Majid I, Imran S. Fractional CO2 laser resurfacing as monotherapy in the treatment of atrophic facial acne scars. *J Cutan Aesthet Surg.* 2014;7(2):87–92.
  13. Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. *J Am Acad Dermatol.* 2008;58(5):719–37; quiz 738-40.
  14. Orringer JS, Kang S, Johnson TM, Karimipour DJ, Hamilton T, Hammerberg C, Voorhees JJ, Fisher GJ. Connective tissue remodeling induced by carbon dioxide laser resurfacing of photo- damaged human skin. *Arch Dermatol.* 2004;140(11):1326–32.
  15. Walsh JT Jr., Deutsch TF. Pulsed CO2 laser tissue ablation: measurement of the ablation rate. *Lasers Surg Med.* 1988;8 (3):264–75.
  16. Matsuda S, Shibayama H, Hisama M, Ohtsuki M, Iwaki M. Inhibitory effects of novel ascorbic derivative VCP-IS-2Na on melanogenesis. *Chem Pharm Bull* 2008;56:292-7.
  17. Burke KE. Interaction of Vit C and E as better Cosmeseuticals. *Dermatol Ther* 2007;20:314-9.
  18. Pinnell SR, Yang HS, Omar M, Riviere NM, DeBuys HV, Walker LC. Topical L ascorbic acid percutaneous absorption studies. *Dermatol Surg* 2001;27:137-42.
-

- 
19. Lee S, Lee J, Choi YW. Skin permeation enhancement of Ascorbyl palmitate by lipohydro gel formulation and electrical assistance. *Bio Pharma Bull* 2007;30:393-6.
  20. Zhang L, Lerner S, Rustrum WV, Hofmann GA. Electroporation mediated topical delivery of Vit C for cosmetic applications. *Bioelectrochem Bioenerg* 1999;48:453-61.
  21. Lee RW, Shen CS, Wang KH, Hu CH, Fang JY. Lasers and microdermabrasion enhance and control topical delivery of Vit C. *J Invest Dermat* 2003;121:1118-25.
  22. Alster TS, Tanzi EL, Lazarus M. The use of fractional laser photothermolysis for the treatment of atrophic scars. *Dermatol Surg* 2007;33:295-9.
  23. Campbell TM, Goldman MP. Adverse Events of Fractionated Carbon Dioxide Laser: Review of 373 Treatments. *Dermatol Surg* 2010;36:1645-50.
  24. Metelitsa AI, Alster TS. Fractionated laser skin resurfacing treatment complications: A review. *Dermatol Surg* 2010;36:299-306.
  25. Hunt A. The role of vitamin C in wound healing. *Br J Surg* 1941;28(111):436–61.
  26. Bloom B, Brauer J, Geronemus R. Ablative fractional resurfacing in the topical drug delivery: An update and outlook. *Dermatol Surg* 2013;39(6):839–48.
  27. Sklar L, Burnett C, Waibel J, Moy R, Ozog D. Laser assisted drug delivery: A review of an evolving technology. *Lasers Surg Med* 2014;46:249–62.
  28. Haedersdal M, Sakamoto F, Farinelli W, Doukas A, Tam J, Anderson R. Fractional CO<sub>2</sub> laser-assisted drug delivery. *Lasers Surg Med* 2010;42:113–22.
  29. Rkein A, Ozog D, Waibel J. Treatment of atrophic scars with fractional CO<sub>2</sub> laser facilitating delivery of topically applied poly-L-lactic acid. *Dermatol Surg* 2014;0:1–8.
-

- 
30. Goodman GJ. Postacne scarring: a review of its pathophysiology and treatment. *Dermatol Surg*. 2000;26:857–71.
  31. Gollnick HP, Finlay AY, Shear N; Global Alliance to Improve Outcomes in Acne. Can we define acne as a chronic disease? If so, how and when? *Am J Clin Dermatol* 2008;9:279-84.
  32. Fife D. Practical evaluation and management of atrophic acne scars: tips for the general dermatologist. *J Clin Aesthet Dermatol*. 2011;4:50–7.
  33. George RM, Sridharan R. Factors Aggravating or Precipitating Acne in Indian Adults: A Hospital-Based Study of 110 Cases. *Indian J Dermatol*. 2018;63(4):328-33
  34. Collier CN, Harper JC, Cafardi JA, Cantrell WC, Wang W, Foster KW, *et al*. The prevalence of acne in adults 20 years and older. *J Am Acad Dermatol* 2008;58:56-9.
  35. Jacob CI, Dover JS, Kaminer MS. Acne scarring: A classification system and review of treatment options. *J Am Acad Dermatol* 2001;45:109-17.
  36. Fabbrocini G, Annunziata MC, D'Arco V, De Vita V, Lodi G, Mauriello MC, Pastore F, Monfrecola G. Acne scars: pathogenesis, classification and treatment. *Dermatology research and practice*. 2010;2010:893080.
  37. Faghihi G, Nouraei S, Asilian A, Keyvan S, Abtahi-naeini B, Rakhshanpour M, Nilforoushzadeh AM, Hosseini SM. Efficacy of punch elevation combined with fractional carbon dioxide laser resurfacing in facial atrophic acne scarring: a randomized split-face clinical study. *Indian J Dermatol*. 2015;60(5):473–8.
  38. Sadick N.S, Cardona A Laser treatment for facial acne scars: A review, *J. Cosmet. Laser Ther*. 2018;20 (7-8):424-35
-

- 
39. Dreno B, Khammari A, Orain N, Noray C, Merial-Kieny C, Mery S, Nocera T. ECCA grading scale: an original validated acne scar grading scale for clinical practice in dermatology. *Dermatology*. 2007;214(1):46-51.
  40. Goodman GJ, Baron JA. Postacne scarring: a qualitative global scarring grading system. *Dermatologic surgery*. 2006;32(12):1458-66.
  41. Goodman GJ, Baron JA. Postacne scarring--a quantitative global scarring grading system. *Journal of cosmetic dermatology*. 2006;5(1):48-52.
  42. Layton A, Dreno B, Finlay AY, Thiboutot D, Kang S, Lozada VT, Bourdès V, Bettoli V, Petit L, Tan J. New Patient-Oriented Tools for Assessing Atrophic Acne Scarring. *Dermatology and therapy*. 2016;6(2):219-33.
  43. Gozali MV, Zhou B. Effective Treatments of Atrophic Acne Scars. *The Journal of Clinical and Aesthetic Dermatology*. 2015;8(5):33-40
  44. Zaleski-Larsen LA, Fabi SG, McGraw T, Taylor M. Acne Scar Treatment: A Multimodality Approach Tailored to Scar Type. *Dermatologic surgery*. 2016; 42 Suppl 2:S139-49.
  45. Cohen BE, Brauer JA, Geronemus RG. Acne scarring: a review of available therapeutic lasers. *Lasers Surg Med*. 2016; 48(2):95–115.
  46. Lee SJ, Kang JM, Chung WS, Kim YK, Kim HS. Ablative non- fractional lasers for atrophic facial acne scars: a new modality of erbium: YAG laser resurfacing in Asians. *Lasers Med Sci*. 2014; 29 (2):615–9.
  47. Tanzi EL, Alster TS. Treatment of atrophic facial acne scars with a dual-mode Er: Yag laser. *Dermatol Surg*. 2002; 28(7):551–5.
  48. Wanitphakdeedecha R, Manuskiatti W, Siriphukpong S, Chen TM. Treatment of punched-out atrophic and rolling acne scars in skin phototypes III, IV, and V with variable square pulse erbium: yttrium-aluminum-garnet laser resurfacing. *Dermatol Surg*. 2009; 35(9):1376–83.
-

- 
49. Woo SH, Park JH, Kye YC. Resurfacing of different types of facial acne scar with short-pulsed, variable-pulsed, and dual-mode Er: YAG laser. *Dermatol Surg.* 2004; 30(4 Pt 1):488–93.
50. Bencini PL, Tournalaki A, Galimberti M, Longo C, Pellacani G, De Giorgi v, Guerriero G. Nonablative fractional photothermolysis for acne scars: clinical and in vivo microscopic documentation of treatment efficacy. *Dermatol Ther.* 2012;25(5):463–7.
51. Gupta, M., Mahajan, V. K., Mehta, K. S., & Chauhan, P. S. (2014). Zinc therapy in dermatology: a review. *Dermatology Research and Practice*, 2014, 709152.
52. Mustoe TA, Cooter RD, Gold MH, Hobbs FD, Ramelet AA, Shakespeare PG, Stella M, Téot L, Wood FM, Ziegler UE, International Advisory Panel on Scar Management. *Plast Reconstr Surg.* 2002; 110(2):560-71.
53. Layton AM, Yip J, Cunliffe WJ. A comparison of intralesional triamcinolone and cryosurgery in the treatment of acne keloids. *Br J Dermatol.* 1994 Apr; 130(4):498-501.
54. Manuskiatti W, Fitzpatrick RE. Treatment response of keloidal and hypertrophic sternotomy scars: comparison among intralesional corticosteroid, 5-fluorouracil, and 585-nm flashlamp-pumped pulsed-dye laser treatments. *Archives of Dermatology.* 2002; 138(9):1149–55.
55. Harris DW, Buckley CC, Ostlere LS, Rustin MH. Topical retinoic acid in the treatment of fine acne scarring. *The British journal of dermatology.* 1991; 125(1):81-2
56. Azzam OA, Bassiouny DA, El-Hawary MS, El Maadawi ZM, Sobhi RM, El-Mesidy MS. Treatment of hypertrophic scars and keloids by fractional carbon dioxide laser: a clinical, histological, and immunohistochemical study. *Lasers Med. Sci.* 2016; 31(1):9-18.
-

- 
57. AlGhamdi KM, AlEnazi MM. Versatile punch surgery. *J Cutan Med Surg*. 2011; 15:87–96.
58. Grevelink JM, White VR. Concurrent use of laser skin resurfacing and punch excision in the treatment of facial acne scarring. *Dermatol Surg*. 1998; 24(5):527-30.
59. Kang WH, Kim YJ, Pyo WS, Park SJ, Kim JH. Atrophic acne scar treatment using triple combination therapy: dot peeling, subcision and fractional laser. *Journal of cosmetic and laser therapy: J Cosmet Dermatol* 2009; 11(4):212-5.
60. Chandrashekar B, Nandini A. Acne scar subcision. *J Cutan Aesthet Surg*. 2010 May;3(2):125-6
61. Kontochristopoulos G, Platsidaki E. Chemical peels in active acne and acne scars. *Clinics in dermatology*. 2017; 35(2):179-82.
62. Hession MT, Graber EM. Atrophic Acne Scarring: A Review of Treatment Options. *The Journal of clinical and aesthetic dermatology*. 2015; 8(1):50-8.
63. Bhardwaj D, Khunger N. An Assessment of the Efficacy and Safety of CROSS Technique with 100% TCA in the Management of Ice Pick Acne Scars. *J Cutan Aesthet Surg*. 2010; 3(2):93-6.
64. Kaplan H, Kaplan L. Combination of microneedle radiofrequency (RF), fractional RF skin resurfacing and multi-source non-ablative skin tightening for minimal-downtime, full-face skin rejuvenation. *J Cosmet Laser Ther*. 2016;18(8):438-41.
-



- 
65. Savardekar P. Microdermabrasion. *Indian J Dermatol Venereol Leprol* 2007;73:277-9
66. Gupta A, Kaur M, Patra S, Khunger N, Gupta S. Evidence-based surgical management of post-acne scarring in skin of color. *J Cutan Aesthet Surg* 2020;13:124-41
67. Kravvas G, Al-Niaimi F. A systematic review of treatments for acne scarring. Part 1: Non-energy-based techniques. *Scars Burn Heal*. 2017 Mar 30;3:2059513117695312
68. Karimipour DJ, Orringer JS. Microdermabrasion. *Plast Reconstr Surg* 2010; 125: 372–7. 20
69. Spencer JM. Microdermabrasion. *Am J Clin Dermatol* 2005; 6: 89–92
70. Meymandi SS, Moosazadeh M, Rezazadeh A. Comparing Two Methods of Cryotherapy and Intense Pulsed Light with Triamcinolone Injection in the Treatment of Keloid and Hypertrophic Scars: A Clinical Trial. *Osong Public Health Res Perspect*. 2016; 7(5):313-9.
71. Ibrahim ZA, El-Tatawy RA, El-Samongy MA, Ali DA. Comparison between the efficacy and safety of platelet-rich plasma vs. microdermabrasion in the treatment of striae distensae: clinical and histopathological study. *J Cosmet Dermatol*. 2015; 14(4):336-46.
72. Wu N, Sun H, Sun Q, Cong L, Liu C, Zheng Y, Ma L, Cong X. A meta-analysis of fractional CO<sub>2</sub> laser combined with PRP in the treatment of acne scar. *Lasers Med Sci*. 2021;36(1):1-12.

- 
73. Boen, M., Jacob, C. A review and update of treatment options using the acne scar classification system. *Dermatologic Surgery*, 2019; 45(3):411–22.
74. Wollina U, Goldman A. Fillers for the improvement in acne scars. *Clinical, Cosmetic and Investigational Dermatology*. 2015;8:493-9.
75. Forbat E, Ali FR, Al-Niaimi F. The role of fillers in the management of acne scars. *Clin Exp Dermatol*. 2017 Jun;42(4):374-80
76. Hasson A, Romero WA. Treatment of facial atrophic scars with Esthelis, a hyaluronic acid filler with polydense cohesive matrix (CPM). *Journal of drugs in dermatology: JDD*. 2010; 9(12):1507-9.
77. Halachmi S, Ben Amitai D, Lapidoth M. Treatment of acne scars with hyaluronic acid: an improved approach. *Journal of drugs in dermatology : JDD*. 2013; 12(7):e121-3.
78. Patel T, Tevet O. Effective treatment of acne scars using pneumatic injection of hyaluronic acid. *Journal of drugs in dermatology: JDD*. 2015; 14(1):74-6.
79. Sadick NS, Cardona A. Laser treatment for facial acne scars: A review. *J Cosmet Laser Ther*. 2018; 20 (7-8):424-35.
80. Omi T, Numano K. The Role of the CO<sub>2</sub> Laser and Fractional CO<sub>2</sub> Laser in Dermatology. *Laser Therapy*. 2014; 23(1):49-60.
81. Abdel-Maguid EM, Awad SM, Hassan YS, El-Mokhtar MA, El-Deek HE, Mekkawy MM. Efficacy of stem cell-conditioned medium vs. platelet-rich plasma as an adjuvant to ablative fractional CO<sub>2</sub> laser resurfacing for atrophic
-

- 
- post-acne scars: a split-face clinical trial. *J Dermatolog Treat.* 2021;32(2):242-9
82. Park CS, Park JH, Kim CR, Lee JH. Objective analysis of volume restoration in atrophic acne scars and skin pores: a split study using human stem cell-conditioned media. *J Dermatolog Treat.* 2021 ;32(1):73-7.
83. Sharma S, Kaur J, Kaur T, Bassi R. Fractional Carbon Dioxide Laser versus Combined Fractional Carbon Dioxide Laser with Platelet-rich Plasma in the Treatment of Atrophic Post-acne Scars: A Split-face Comparative Study. *J Cutan Aesthet Surg.* 2021;14(1):41-6
84. Wei M, Li L, Zhang XF, Li M, Wang B, Yan Y. Fusidic acid cream comparatively minimizes signs of inflammation and postinflammatory hyperpigmentation after ablative fractional CO<sub>2</sub> laser resurfacing in Chinese patients: A randomized controlled trial. *J Cosmet Dermatol.* 2021;20(6):1692-9.
85. Cao Y, Wang P, Zhang G, Hu C, Zhang H, Wang X. Administration of skin care regimens containing  $\beta$ -glucan for skin recovery after fractional laser therapy: A split-face, double-blinded, vehicle-controlled study. *J Cosmet Dermatol.* 2021;20(6):1756-62
86. Sirithanabadeekul P, Tantrapornpong P, Rattakul B, Sutthipisal N, Thanasarnaksorn W. Comparison of Fractional Picosecond 1064-nm Laser and Fractional Carbon Dioxide Laser for Treating Atrophic Acne Scars: A Randomized Split-Face Trial. *Dermatol Surg.* 2021;47(2):e58-e65.
87. Zang H, Xu YN. Effectiveness of CO<sub>2</sub> laser therapy in treating acne depressed scar: A protocol of systematic review. *Medicine (Baltimore).* 2021;100(3):e23732
88. Yang Z, Jiang S, Zhang Y, Chen Y, Tan Y, Su H, Xiong Y, Li Q, He L. Self-contrast study of pinprick therapy combined with super pulse fractional
-

- 
- CO<sub>2</sub> laser for the treatment of atrophic acne scars. *J Cosmet Dermatol*. 2021;20(2):481-90
89. Zhang DD, Zhao WY, Fang QQ, Wang ZC, Wang XF, Zhang MX, Hu YY, Zheng B, Tan WQ. The efficacy of fractional CO<sub>2</sub> laser in acne scar treatment: A meta-analysis. *Dermatol Ther*. 2021;34(1):e14539.
90. El-Hawary EE, Nassar S, Hodeib AA, Shareef MM, Fawzy MM. Ablative Fractional Carbon Dioxide Laser and Autologous Platelet-Rich Plasma in the Treatment of Atrophic Acne Scars: A Comparative Clinico-Immuno-Histopathological Study. *Lasers Surg Med*. 2021;53(4):458-67
91. Mirza HN, Mirza FN, Khatri KA. Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients. *Dermatol Ther*. 2021;34(1):e14432.
92. Pooja T, T. Gopal K V, Rao T N, Devi B G, Kumar S A. A randomized study to evaluate the efficacy fractional CO<sub>2</sub> laser, microneedling and platelet rich plasma in post-acne scarring. *Indian Dermatol Online J* 2020;11:349-54
93. Godara S, Arora S, Dabas R, Arora G, Renganathan G, Choudhary R. A comparative study on the efficacy of fractional CO<sub>2</sub> laser and fractional CO<sub>2</sub> laser with autologous platelet-rich plasma in scars. *Indian Dermatol Online J* 2020;11:930-6
94. Kwon HH, Yang SH, Lee J, Park BC, Park KY, Jung JY, Bae Y, Park GH. Combination Treatment with Human Adipose Tissue Stem Cell-derived Exosomes and Fractional CO<sub>2</sub> Laser for Acne Scars: A 12-week Prospective, Double-blind, Randomized, Split-face Study. *Acta Derm Venereol*. 2020 ;100(18):adv00310.
95. Cenk H, Sarac G. Effectiveness and safety of 2940-nm multifractional Er: YAG laser on acne scars. *Dermatol Ther*. 2020 33(6):e14270
96. Tatlıparmak A, Aksoy B, Shishehgarhaneh LR, Gökdemir G, Koç E. Use of combined fractional carbon dioxide laser and fractional microneedle
-

- 
- radiofrequency for the treatment of acne scars: A retrospective analysis of 1-month treatment outcome on scar severity and patient satisfaction. *J Cosmet Dermatol*. 2020;19(1):115-121.
97. Neinaa YME, Al-Khayat LA, Suliman GAM, Ameen TE. Fractional carbon dioxide laser-assisted delivery of lyophilized-growth factors is a promising treatment modality of post-acne scars. *Dermatol Ther*. 2020;33(6):e14488.
98. Kim J, Lee YI, Kim J, Jung JY, Lee WJ, Lee JH. Safety of Combined Fractional Microneedle Radiofrequency and CO<sub>2</sub> as an Early Intervention for Inflammatory Acne and Scarring Treated With Concomitant Isotretinoin. *Dermatol Surg*. 2020;46(10):e71-e77.
99. Mahamoud WA, El Barbary RA, Ibrahim NF, Akmal EM, Ibrahim SM. Fractional carbon dioxide laser combined with intradermal injection of autologous platelet-rich plasma versus noncross-linked hyaluronic acid in the treatment of atrophic postacne scars: A split face study. *J Cosmet Dermatol*. 2020 ;19(6):1341-52.
100. Abdel Kareem IM, Fouad MA, Ibrahim MK. Effectiveness of subcision using carboxytherapy plus fractional carbon dioxide laser resurfacing in the treatment of atrophic acne scars: comparative split face study. *J Dermatolog Treat*. 2020;31(3):296-9
101. Koren A, Isman G, Cohen S, Bar Ilan E, Salameh F, Sprecher E, Artzi O. Efficacy of a combination of diluted calcium hydroxylapatite-based filler and an energy-based device for the treatment of facial atrophic acne scars. *Clin Exp Dermatol*. 2019;44(5):e171-e176.
102. Wanitphakdeedecha R, Iamphonrat T, Phothong W, Eimpunth S, Manuskiatti W. Local and systemic effects of low-level light therapy with light-emitting diodes to improve erythema after fractional ablative skin resurfacing: a controlled study. *Lasers Med Sci*. 2019;34(2):343-51
-

- 
103. Arsiwala SZ, Desai SR. Fractional Carbon Dioxide Laser: Optimizing Treatment Outcomes for Pigmented Atrophic Acne Scars in Skin of Color. *J Cutan Aesthet Surg*. 2019;12(2):85-94
104. Lueangarun, S., Srituravanit, A., & Tempark, T. Efficacy and safety of moisturizer containing 5% panthenol, madecassoside, and copper-zinc-manganese versus 0.02% triamcinolone acetonide cream in decreasing adverse reaction and downtime after ablative fractional carbon dioxide laser resurfacing: A split-face, double-blinded, randomized, controlled trial. *J. Cosmet. Dermatol*, 2019;18(6):1751-7.
105. Chang, H.-C., Sung, C.-W., & Lin, M.-H. Efficacy of autologous platelet-rich plasma combined with ablative fractional carbon dioxide laser for acne scars: A systematic review and meta-analysis *Aesthet. Surg. J.* 2019;39(7): NP279–NP287.
106. Mu YZ, Jiang L, Yang H. The efficacy of fractional ablative carbon dioxide laser combined with other therapies in acne scars. *Dermatol Ther*. 2019;32(6):e13084.
107. Chiwo, F. S., Guevara, E., Ramírez-Elías, M. G., Castillo-Martínez, C. C., Osornio-Martínez, C. E., Cabrera-Alonso, R., Pérez-Atamoros, F., & González, F. J. Use of Raman spectroscopy in the assessment of skin after CO2 ablative fractional laser surgery on acne scars. *Skin Res Technol* 2019; 25(6):805–9.
108. Galal O, Tawfik AA, Abdalla N, Soliman M. Fractional CO2 laser versus combined platelet-rich plasma and fractional CO2 laser in treatment of acne scars: Image analysis system evaluation. *J Cosmet Dermatol*. 2019;18(6):1665-71.
109. Asri EA, Widayati RI, Malik DA. Effectiveness of combined 10,600 nm fractional CO2 and 1540 nm erbium GaAs laser therapy on acne scar score
-

- 
- alteration in patients with atrophic acne scars. *Turk J Dermatol* 2019;13:126-30
110. Al Taweel AI, Al Refae AA, Hamed AM, Kamal AM. Comparative study of the efficacy of Platelet-rich plasma combined with carboxytherapy vs its use with fractional carbon dioxide laser in atrophic acne scars. *J Cosmet Dermatol*. 2019;18(1):150-5.
111. Abou Eitta RS, Ismail AA, Abdelmaksoud RA, Ghezlan NA, Mehanna RA. Evaluation of autologous adipose-derived stem cells vs. fractional carbon dioxide laser in the treatment of post acne scars: a split-face study. *Int J Dermatol*. 2019;58(10):1212-22
112. Xu Y, Deng Y. Ablative Fractional CO<sub>2</sub> Laser for Facial Atrophic Acne Scars. *Facial Plast Surg*. 2018;34(2):205-19.
113. Alser OH, Goutos I. The evidence behind the use of platelet-rich plasma (PRP) in scar management: a literature review. *Scars Burn Heal*. 2018;4:2059513118808773.
114. Ansari F, Sadeghi-Ghyassi F, Yaaghoobian B. The clinical effectiveness and cost-effectiveness of fractional CO<sub>2</sub> laser in acne scars and skin rejuvenation: A meta-analysis and economic evaluation. *J Cosmet Laser Ther*. 2018;20(4):248-51.
115. Elsaie ML, Ibrahim SM, Saudi W. Ablative Fractional 10 600 nm Carbon Dioxide Laser Versus Non-ablative Fractional 1540 nm Erbium-Glass Laser in Egyptian Post-acne Scar patients. *J Lasers Med Sci*. 2018;9(1):32-5
116. Saeed AHM, Alsaiani SA. The efficacy of fractional CO<sub>2</sub> laser resurfacing in the treatment of facial acne scars. *Int J Med Sci Public Health* 2018;7(8):630-637.
117. Bhat YJ, Latief I, Hassan I. Update on etiopathogenesis and treatment of Acne. *Indian J Dermatol Venereol Leprol*. 2017;83(3):298-306.
-

- 
118. Nilforoushzadeh MA, Faghihi G, Jaffary F, Haftbaradaran E, Hoseini SM, Mazaheri N. Fractional Carbon Dioxide Laser and its Combination with Subcision in Improving Atrophic Acne Scars. *Adv Biomed Res.* 2017;6:20.
119. Kar BR, Raj C. Fractional CO<sub>2</sub> Laser vs Fractional CO<sub>2</sub> with Topical Platelet-rich Plasma in the Treatment of Acne Scars: A Split-face Comparison Trial. *J Cutan Aesthet Surg.* 2017 ;10(3):136-44.
120. Ochi H, Tan L, Tan WP, Goh CL. Treatment of Facial Acne Scarring With Fractional Carbon Dioxide Laser in Asians, a Retrospective Analysis of Efficacy and Complications. *Dermatol Surg.* 2017;43(9):1137-43
121. Dai R, Xie H, Hua W, Li XH, Li L. The efficacy and safety of the fractional radiofrequency technique for the treatment of atrophic acne scar in Asians: A meta-analysis. *J Cosmet Laser Ther.* 2017;19(6):337-44.
122. Toyos MM. Continuous Wave Fractional CO<sub>2</sub> Laser for the Treatment of Upper Eyelid Dermatochalasis and Periorbital Rejuvenation. *Photomed Laser Surg.* 2017;35(5):278-81
123. Taylor MB, Zaleski-Larsen L, McGraw TA. Single Session Treatment of Rolling Acne Scars Using Tumescence Anesthesia, 20% Trichloroacetic Acid Extensive Subcision, and Fractional CO<sub>2</sub> Laser. *Dermatol Surg.* 2017;43 Suppl 1:S70-S74
124. Tenna S, Cogliandro A, Barone M, Panasiti V, Tirindelli M, Nobile C, Persichetti P. Comparative Study Using Autologous Fat Grafts Plus Platelet-Rich Plasma With or Without Fractional CO<sub>2</sub> Laser Resurfacing in Treatment of Acne Scars: Analysis of Outcomes and Satisfaction With FACE-Q. *Aesthetic Plast Surg.* 2017;41(3):661-6.
125. Yalici-Armagan B, Elcin G. Fractional carbon dioxide laser for facial rejuvenation: A prospective study to evaluate the efficacy and the safety. *J Cosmet Laser Ther.* 2018;20(1):2-8.
-



- 
126. Kroepfl L, Emer JJ. Combination Therapy for Acne Scarring: Personal Experience and Clinical Suggestions. *J Drugs Dermatol*. 2016;15(11):1413-9.
127. Lee SJ, Suh DH, Chang KY, Kim HJ, Kim TI, Jeong KH, Shin MK, Song KY. The efficacy and safety of subcision using CO<sub>2</sub> gas combined with fractional laser for acne scars: Clinical and microscopic evaluation. *J Cosmet Laser Ther*. 2016;18(7):417-420.
128. Hohenleutner U, Hohenleutner S, Baumler W, Landthaler M. Fast and effective skin ablation with an Er:YAG laser: determination of ablation rates and thermal damage zones. *Lasers Surg Med*. 1997;20(3):242-7.
129. Alster TS, Lupton JR. Erbium:YAG cutaneous laser resurfacing. *Dermatologic clinics*. 2001;19(3):453-66.
130. Ross EV, Miller C, Meehan K, Pac, McKinlay J, Sajben P, et al. One-pass CO<sub>2</sub> versus multiple-pass Er:YAG laser resurfacing in the treatment of rhytides: a comparison side-by-side study of pulsed CO<sub>2</sub> and Er:YAG lasers. *Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al]*. 2001;27(8):709-15.
131. Manuskiatti W, Siriphukpong S, Varothai S, Wanitphakdeedecha R, Fitzpatrick RE. Effect of pulse width of a variable square pulse (VSP) erbium:YAG laser on the treatment outcome of periorbital
-

---

wrinkles in Asians. International journal of dermatology.  
2010;49(2):200-6.

132. Raulin C, Grema H. Single-pass carbon dioxide laser skin resurfacing combined with cold-air cooling: Efficacy and patient satisfaction of a prospective side-by-side study. Archives of dermatology. 2004;140(11):1333-6.
133. Nelson S. An introduction to laser and laser-tissue interactions in dermatology. Principles and Practices in Cutaneous Laser Surgery. 2005;33:59.
134. Gold MH. Update on fractional laser technology 2009. 42-50 p. 102.
135. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers in surgery and medicine. 2004;34(5):426-38.
136. Sardana K, Garg VK, Arora P, Khurana N. Histological validity and clinical evidence for use of fractional lasers for acne scars. Journal of Cutaneous and Aesthetic Surgery. 2012;5(2):75-90.
137. Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: Nonablative, fractional, and ablative laser resurfacing. J Am Acad Dermatol. 2008; 58(5):719-37.

- 
138. Nelson AA, Beynet D, Lask GP. A novel non-invasive radiofrequency dermal heating device for skin tightening of the face and neck. *J Cosmet Laser Ther.* 2015;17(6):307-12.
139. Zelickson BD, Kist D, Bernstein E, Brown DB, Ksenzenko S, Burns J, Kilmer S, Mehregan D, Pope K. Histological and ultrastructural evaluation of the effects of a radiofrequency-based nonablative dermal remodeling device: a pilot study. *Arch Dermatol.* 2004; 140(2):204-9.
140. Taub AF, Garretson CB. Treatment of Acne Scars of Skin Types II to V by Sublative Fractional Bipolar Radiofrequency and Bipolar Radiofrequency Combined with Diode Laser. *J Clin Aesthet Dermatol.* 2011 Oct;4(10):18-27.
141. Yeung CK, Chan NP, Shek SY, Chan HH. Evaluation of combined fractional radiofrequency and fractional laser treatment for acne scars in Asians. *Lasers Surg Med.* 2012 Oct;44(8):622-30.
142. Verner I. Clinical evaluation of the efficacy and safety of fractional bipolar radiofrequency for the treatment of moderate to severe acne scars. *Dermatol Ther.* 2016; 29(1):24-7.
143. Anderson RR, Parrish JA. Selective photothermolysis: precise microsurgery by selective absorption of pulsed radiation. *Science.* 1983; 220(4596):524-7
144. Grunewald S, Bodendorf M, Illes M, Kendler M, Simon JC, Paasch U. In vivo wound healing and dermal matrix remodelling in response to fractional CO(2) laser intervention: clinicopathological correlation in non-facial skin. *Int J Hyperthermia.* 2011;27(8):811-8
-

- 
145. Hantash BM, Bedi VP, Kapadia B, Rahman Z, Jiang K, Tanner H, Chan KF, Zachary CB. In vivo histological evaluation of a novel ablative fractional resurfacing device. *Lasers Surg Med.* 2007; 39(2):96-107.
  146. Fisher GJ, Varani J, Voorhees JJ. Looking older: fibroblast collapse and therapeutic implications. *Arch Dermatol.* 2008; 144(5):666-72.
  147. Petrov A, Pljakovska V. Fractional Carbon Dioxide Laser in Treatment of Acne Scars. *Open Access Maced J Med Sci.* 2016; 4(1):38-42.
  148. Shi J, Li J, Huang H, Permatasari F, Liu J, Xu Y et al. The efficacy of fractional carbon dioxide (CO<sub>2</sub>) laser combined with terbinafine hydrochloride 1% cream for the treatment of onychomycosis. *J Cosmet Laser Ther.* 2017; 19(6):353-9.
  149. Manuskiatti W, Triwongwaranat D, Varothai S, Eimpunth S, Wanitphakdeedecha R. Efficacy and safety of a carbon-dioxide ablative fractional resurfacing device for treatment of atrophic acne scars in Asians. *J Am Acad Dermatol.* 2010;63(2):274-83.
  150. Ramsdell WM. Fractional CO<sub>2</sub> Laser Resurfacing Complications. *Semin Plast Surg.* 2012;26(3):137-40
  151. Chan HH, Manstein D, Yu CS, Shek S, Kono T, Wei WI. The prevalence and risk factors of post-inflammatory hyperpigmentation after fractional resurfacing in Asians. *Lasers Surg Med.* 2007; 39(5):381-5.
  152. Ravetti S, Clemente C, Brignone S, Hergert L, Allemandi D, Palma S. Ascorbic Acid in Skin Health. *Cosmetics.* 2019; 6(4):58.
  153. Janda K, Kasprzak M, Wolska J. [Vitamin C– structure, properties, occurrence and functions]. *Pomeranian J Life Sci.* 2015; 61(4):419-25.
  154. Enescu C D, Bedford L. M, Potts G, Fahs, F. A review of topical vitamin C derivatives and their efficacy. *J Cosmet Dermatol.* 2021
  155. Pullar JM, Carr AC, Vissers MCM. The Roles of Vitamin C in Skin Health. *Nutrients.* 2017;9(8):866.
-

- 
156. Humbert PG, Haftek M, Creidi P, Lapière C, Nusgens B, Richard A, Schmitt D, Rougier A, Zahouani H. Topical ascorbic acid on photoaged skin. Clinical, topographical and ultrastructural evaluation: double-blind study vs. placebo. *Exp Dermatol*. 2003;12(3):237-44.
157. Waibel JS, Mi QS, Ozog D, Qu L, Zhou L, Rudnick A, Al-Niaimi F, Woodward J, Campos V, Mordon S. Laser-assisted delivery of vitamin C, vitamin E, and ferulic acid formula serum decreases fractional laser postoperative recovery by increased beta fibroblast growth factor expression. *Lasers Surg Med*. 2016;48(3):238-44.
158. Al-Niaimi F, Chiang NYZ. Topical Vitamin C and the Skin: Mechanisms of Action and Clinical Applications. *J Clin Aesthet Dermatol*. 2017;10(7):14-7.
159. Telang PS. Vitamin C in dermatology. *Indian Dermatol Online J* 2013; 4:143-6.
160. Yun IS, Yoo HS, Kim YO, Rah DK. Improved scar appearance with combined use of silicone gel and vitamin C for Asian patients: a comparative case series. *Aesthetic Plast Surg*. 2013; 37(6):1176-81
161. Akita S, Akino K, Hirano A. Basic Fibroblast Growth Factor in Scarless Wound Healing. *Adv Wound Care (New Rochelle)*. 2013; 2(2):44-9.
162. Hsiao CY, Huang CH, Hu S, Ko YS, Sung HC, Huang SY. Skin pretreatment with lasers promotes the transdermal delivery of vitamin C derivatives. *Lasers Med Sci*. 2011; 26(3):369-76.
163. Chawla S. Split Face Comparative Study of Microneedling with PRP Versus Microneedling with Vitamin C in Treating Atrophic Post Acne Scars. *J Cutan Aesthet Surg*. 2014 ;7(4):209-12
-

# ANNEXURES



---

## ANNEXURE I

### PROFORMA

**Name:** \_\_\_\_\_ **Age:** \_\_\_\_\_ **Sex:** M/F

**OP No.:** \_\_\_\_\_ **Education:** \_\_\_\_\_

**Address:** \_\_\_\_\_ **Occupation:** \_\_\_\_\_

**Ph No.:** \_\_\_\_\_

**Email id:** \_\_\_\_\_

**C/C:-** \_\_\_\_\_

**HOP:-** \_\_\_\_\_

**Drug history:-** \_\_\_\_\_

**Past history:-** DM/ HTN/ TB/ Epilepsy/ Asthma/ Atopy.

1 Isotretinoin used

(1) Yes..... Duration ..... (2) No [ ]

2 Herpes infections (1) Yes..... (2) No [ ]

3 Skin resurfacing procedures (1) Yes....when..... (2) No [ ]

4 Skin Malignancy

(1) Yes.....when..... (2) No [ ]

5 Keloid/ Hypertrophic scar (1) Yes..... (2) No [ ]

---

6 Duration of lesion

(1) < 5 years

(2) 5-10 years

(3) >10 years Duration

**Family history:-** DM/ HTN/ TB/ Epilepsy/ Asthma/ Atopy.

**Personal history:-**

Diet – veg/ non-veg/ mixed

Appetite –

Sleep – adequate/ disturbed

Bowel & Bladder –Other habits –

**Menstrual History :-**

**Obstetric History:-**



---

**Occupational History:-**

1. Exposure to sunlight:                      yes/ no.
2. Duration of exposure:
3. Type of exposure:                      intermittent/ continuous/ seasonal.
4. Usage of sunscreen:                      yes/ no.
5. Effect to daily activity :

(1) None (2) Minimal (3) Mild (4) Moderate (5) Severe

**General physical examination:-**

PR =    bpm

BP =    /    mmHg

RR =    cpm

Temperature =

P I C C L E

Others –

---

**Systemic examination:-**

CVS –

RS –

P/A –

CNS –

**Local examination:-**

Skin –

Fitzpatrick Skin type -

Hair –

Oral mucosa –

Nails –

**Acne Scar**

**1. Type of acne scars**

- (1) Ice-pick
- (2) Boxcar
- (3) Rolling
- (4) Ice-pick + Boxcar
- (5) Ice-pick + Rolling
- (6) Boxcar + Rolling
- (7) Ice-pick + Boxcar + Rolling

**2. Qualitative Scar grading :**

- a. Macular Disease      b. Mild Disease.      c. Moderate Disease      d. Severe Disease

**3. Pain score and Level of burning/stinging sensation**

- Pain score (0-10):

Right.....Left.....

- Level of burning/stinging sensation:

Right..... Left.....

---

Side	Measurement	Before	1 month Post- Treatment	% Change From Baseline	3 months Post- Treatment	% Change From Baseline
Right	Texture(rough)					
	Scar Volume					
	Melanin(average)					
Left	Texture(rough)					
	Scar Volume					
	Melanin(average)					

Adverse effects	1 <sup>st</sup> session		2 <sup>nd</sup> session		3 <sup>rd</sup> session	
	Day 1	Day 7	Day 1	Day 7	Day 1	Day 7
Erythema (0-10)						
Edema (0-10)						
PIH (0-10)						
Oozing/Crusting (Y=Yes, No=Absent)						
Petechiae (Y=Yes, No=Absent)						

---

Skin Infection						
(Y=Yes, No=Absent)						

---

---

Side	Satisfaction scores at 1 month Post-treatment (0-10)	Satisfaction scores 3 months post-treatment (0-10)	Satisfaction scores at 6 months Post-treatment (0-10)
Left			
Right			

---

## ANNEXURE II

### CONSENT FORM

#### **A PROSPECTIVE STUDY TO COMPARE RESURFACING OF FACIAL ACNE SCARS IN ADULTS USING FRACTIONAL CO2 LASER AS MONOTHERAPY VS FRACTIONAL CO2 LASER WITH TOPICAL VITAMIN C SERUM IN A TERTIARY HEALTH CARE CENTRE**

I, Mr./Mrs./Ms.\_\_\_\_\_, aged\_\_years, S/D/o\_\_\_\_, & a resident of \_\_\_\_

—

\_\_\_\_\_, do hereby declare  
that I am voluntarily giving my consent to participate/ let my son/ daughter  
to participate in the study of “A PROSPECTIVE STUDY TO COMPARE  
RESURFACING OF FACIAL ACNE SCARS IN ADULTS USING  
FRACTIONAL CO2 LASER AS MONOTHERAPY VS FRACTIONAL  
CO2 LASER WITH TOPICAL VITAMIN C SERUM IN A TERTIARY  
HEALTH CARE CENTRE”.

I have been explained in my own language about the nature of my skin  
condition, its prognosis, the treatment options available & their respective  
side effects. I have also been explained to my full satisfaction, in my own  
language about the procedure involved in the study. I have been explained  
that my refusal to consent is however not going to affect my / my patient’s  
right to receive treatment from the department.

---

I do hereby declare that I will provide complete medical history of the disease, allow myself/ my patient to undergo clinical examination & allow collection of necessary clinical material by the treating Doctor.

I also hereby accord consent to be photographed as & when necessary for the purpose of the study. However, these photographs have to be used only for teaching purposes, clinical presentations & publications but not for advertisements or any other commercial purposes.

Name of the declarant / guardian \_\_\_\_\_

Signature of the declarant / guardian \_\_\_\_\_

Name of the witness: \_\_\_\_\_

Signature of the witness: \_\_\_\_\_

Name & Signature of the investigator: \_\_\_\_\_

Date: \_\_\_\_\_

Place: SDUAHER, KOLAR.

---

## ANNEXURE III

### **PATIENT INFORMATION SHEET**

**Study title: A PROSPECTIVE STUDY TO COMPARE RESURFACING OF FACIAL ACNE SCARS IN ADULTS USING FRACTIONAL CO2 LASER AS MONOTHERAPY VS FRACTIONAL CO2 LASER WITH TOPICAL VITAMIN C SERUM IN A TERTIARY HEALTH CARE CENTRE**

**Study site:** R.L Jalappa Hospital , Tamaka, Kolar.

**Aim:**

1. To Assess the efficacy and safety of Fractional CO2 Laser as Monotherapy and Fractional CO2 Laser in combination with Topical Vitamin C Serum in the treatment of Atrophic Facial Acne Scars.
2. To Assess post laser adverse effects and healing of Fractional CO2 Laser as Monotherapy and Fractional Co2 Laser in combination with Topical Vitamin C Serum in the treatment of Atrophic Facial Acne Scars.

Please read the following information and discuss with your family members. You can ask any question regarding the study. If you agree to participate in this study we will collect information(as per proforma) from



---

you. Relevant blood investigations will be carried out if required. This information collected will be used for dissertation and publication only.

All information collected from you will be kept confidential and will not be disclosed to any outsider. Your identity will not be revealed. The expenses required for the above investigations will be funded by the study investigator. This study has been reviewed by the Institutional Ethics Committee and you are free to contact the member of the Institutional Ethics Committee. There is no compulsion to agree to this study. The care you will get will not change if you don't wish to participate. You are required to sign/ provide thumb impression only if you voluntarily agree to participate in this study.

**For any further clarification you can contact the study investigator:**

Name- Dr.Chandrika Nayyar

Mobile No. - 9561389876

Email ID- dr.chandrikamehta@gmail.com

---

## ANNEXURE IV

### KEY TO MASTER CHART

**GROUP 1-** participants will be treated with Fractional Co2 Laser

**GROUP 2-** participants will be treated with Fractional Co2 Laser in combination with Topical Vitamin C Serum within 2 minutes immediately after laser and daily for 4 months

#### AGE GROUP

≤20yrs	1
21-25yrs	2
26-30yrs	3
>30yrs	4

#### Sex

Female	1
Male	2

#### Marital status

Married	1
Unmarried	2

---

### Occupation

Professional	1
Skilled worker	2
Unskilled worker	3
Housewife	4
Student	5

### Percentage of improvement after 6 months

<25%	1
25-50%	2
50-75%	3
>75%	4

### Patient satisfaction

Unsatisfied	1
Slightly Satisfied	2
Satisfied	3
Very Satisfied	4

### Side Effects

Nil	1
PIH	2
Acneiform Eruption	3

---

---

---

---

S.No.	UHID No.	Age Group	Sex	Marital Status	Occupation	Group	Fitzpatrick Skin Type	Acne Scar Score	Improvement after 6 months	Patient Satisfaction
1	733288	1	1	2	5	1	IV	4	3	3
2	591338	3	1	2	1	2	III	3	3	2
3	687821	2	2	2	2	1	IV	4	2	2
4	652508	1	1	2	5	1	III	4	3	2
5	678284	3	1	2	1	1	IV	4	3	3
6	713294	2	1	2	3	1	IV	3	4	3
7	722451	3	1	1	1	2	IV	3	3	3
8	782692	2	2	2	1	2	III	3	3	2
9	794075	2	1	2	5	1	IV	4	4	3
10	792889	2	1	2	1	1	IV	4	2	0
11	788925	3	2	1	1	2	IV	4	3	2
12	592182	2	1	1	4	2	IV	4	3	2
13	550041	2	2	2	1	1	II	3	4	3
14	840687	2	1	2	1	1	IV	3	2	0
15	841318	1	2	2	5	2	IV	4	1	1
16	825787	2	2	2	3	2	IV	4	3	2
17	758672	3	2	1	3	1	IV	4	2	1

18	843435	3	1	1	1	1	II	3	1	1
19	819894	3	1	1	1	2	IV	4	3	1
20	838811	2	2	2	5	1	III	4	1	1
21	839246	2	2	1	3	2	IV	4	3	2
22	589262	3	2	1	1	2	IV	4	3	3
23	693451	2	1	1	4	1	IV	3	2	2
24	531120	2	1	2	1	2	IV	3	4	3
25	839578	3	2	2	1	1	II	4	3	3
26	541808	2	1	2	1	1	IV	4	2	2
27	616818	4	2	2	2	1	IV	4	2	2
28	563913	1	2	2	5	2	III	4	4	2
29	839709	4	1	1	1	1	IV	3	3	2
30	693563	3	1	1	4	2	IV	4	3	3
31	522295	1	1	2	5	2	IV	4	3	2
32	885958	2	1	1	4	2	IV	4	4	2
33	814619	2	1	2	1	1	IV	4	3	3
34	822649	2	2	2	5	1	IV	4	3	2
35	821463	2	2	2	1	1	III	4	3	3
36	849262	2	1	2	5	2	III	3	4	3

37	8489611	3	2	2	3	1	IV	3	4	3
38	877782	3	1	2	1	2	III	3	3	3
39	878220	2	2	2	5	1	IV	4	2	3
40	881816	2	2	2	1	2	IV	4	4	3
41	883919	1	1	2	5	2	IV	4	3	3
42	889804	1	2	2	5	2	IV	4	3	3
43	884304	3	2	1	1	1	IV	4	2	3
44	875233	4	2	1	1	2	IV	4	2	1
45	890987	3	1	1	1	2	IV	3	3	2
46	887777	3	2	2	1	2	IV	4	4	3
47	892312	2	1	2	5	2	IV	4	4	3
48	893169	3	2	2	1	1	IV	4	3	2
49	893434	3	2	2	3	2	IV	4	3	2
50	866845	2	2	2	5	2	IV	4	4	3
51	886275	1	1	2	5	1	III	4	2	2
52	883193	1	1	2	5	1	III	4	3	2
53	879212	4	2	1	3	2	III	4	4	3
54	884287	4	1	1	1	1	IV	4	3	3
55	882702	3	2	2	1	2	IV	4	3	3



56	882024	3	1	1	4	2	II	4	3	3
57	886714	2	1	1	1	1	IV	4	1	1
58	898632	3	2	2	3	1	III	3	2	2
59	866845	4	2	1	1	1	IV	4	3	2
60	887388	4	1	1	3	2	IV	4	4	3
61	897777	3	2	2	2	2	III	4	3	3
62	902345	3	1	1	1	1	IV	4	2	2
63	905024	2	1	2	5	1	III	4	4	3
64	904836	4	1	1	1	2	IV	3	3	3
65	905245	2	2	2	1	2	IV	4	4	3
66	927819	3	1	1	2	1	III	4	2	3
67	906987	3	2	1	1	2	III	4	4	3
68	906544	3	2	1	1	1	III	3	2	2
69	907661	2	1	2	5	2	IV	4	4	3
70	833901	2	2	2	1	1	IV	3	4	2
71	903305	2	1	2	1	2	II	4	4	3
72	883698	1	1	2	5	1	IV	4	4	3
73	914962	2	1	2	5	2	IV	4	4	3
74	919807	2	1	2	1	2	IV	4	4	2

75	926152	3	1	2	1	1	III	4	4	3
76	926786	2	2	2	5	1	IV	4	1	0

S.No.	Group	Oedema (D1 After 1 <sup>st</sup> Session)	Oedema (D7 After 1 <sup>st</sup> Session)	Oedema (D1 After 2 <sup>nd</sup> Session)	Oedema (D7 After 2 <sup>nd</sup> Session)	Oedema (D1 After 3 <sup>rd</sup> Session)	Oedema (D1 After 3 <sup>rd</sup> Session)	Erythema (D1 After 1 <sup>st</sup> Session)	Erythema (D7 After 1 <sup>st</sup> Session)	Erythema (D1 After 2 <sup>nd</sup> Session)	Erythema (D7 After 2 <sup>nd</sup> Session)	Erythema (D1 After 3 <sup>rd</sup> Session)	Erythema (D7 After 3 <sup>rd</sup> Session))	Side Effects
1	1	6	1	5	0	4	1	7	2	6	1	6	1	1
2	2	6	0	4	0	4	0	7	0	5	0	4	0	1
3	1	7	2	7	1	7	1	7	3	6	3	6	2	2
4	1	5	0	5	0	5	0	7	1	6	1	6	1	1
5	1	4	0	4	0	4	0	7	1	7	1	6	1	1
6	1	5	0	5	0	5	0	7	0	6	0	6	0	1
7	2	5	0	4	0	4	0	7	1	5	1	5	0	1
8	2	6	0	4	0	4	0	7	1	7	1	5	0	1
9	1	5	1	3	0	3	0	7	2	5	1	5	1	3
10	1	7	2	6	1	6	1	7	3	6	2	6	1	1
11	2	7	1	6	0	5	1	8	2	6	0	6	0	1
12	2	5	0	4	0	4	0	5	1	4	0	4	0	1
13	1	6	1	6	1	6	0	7	2	6	1	6	0	1
14	1	7	2	7	0	6	1	8	3	8	2	8	2	2
15	2	5	0	4	0	5	0	7	1	5	0	5	0	1

16	2	6	0	4	0	4	0	7	0	4	0	4	0	1
17	1	5	1	5	1	5	1	7	2	5	1	5	1	2
18	1	3	0	3	0	3	0	5	1	4	1	4	0	1
19	2	2	0	2	0	2	0	4	1	3	0	3	0	1
20	1	3	0	3	0	3	0	4	1	4	1	4	0	1
21	2	3	0	3	0	3	0	4	0	3	0	3	0	1
22	2	4	0	4	0	4	0	4	0	4	0	3	0	1
23	1	2	0	2	0	2	0	5	1	4	0	4	0	1
24	2	1	0	1	0	1	0	3	0	2	0	2	0	1
25	1	4	0	4	0	4	0	7	2	5	1	4	0	1
26	1	3	0	3	0	3	0	5	2	4	1	4	1	1
27	1	5	1	5	1	5	1	6	2	5	1	5	1	2
28	2	3	0	2	0	2	0	3	0	3	0	3	0	1
29	1	4	0	4	0	4	0	5	1	5	1	5	1	1
30	2	2	0	2	0	2	0	3	0	2	0	2	0	1
31	2	5	0	5	0	5	0	6	1	5	0	4	0	1
32	2	3	0	3	0	2	0	3	0	3	0	2	0	1
33	1	5	1	5	1	4	0	5	1	5	1	4	1	1
34	1	9	3	7	1	8	2	9	4	8	2	8	1	1



54	1	3	0	3	0	3	0	3	0	3	0	3	0	1
55	2	9	0	7	0	7	0	9	2	7	1	7	1	1
56	2	5	0	5	0	4	0	6	0	5	0	5	0	1
57	1	7	2	6	2	6	2	7	3	7	3	7	2	2
58	1	3	0	3	0	3	0	4	0	4	0	4	0	1
59	1	2	0	2	0	2	0	3	0	3	0	2	0	1
60	2	3	0	2	0	2	0	3	0	2	0	2	0	1
61	2	2	0	2	0	2	0	2	0	2	0	2	0	1
62	1	6	0	5	0	5	0	7	1	7	1	7	1	1
63	1	4	0	4	0	3	0	5	1	4	1	4	1	1
64	2	3	1	3	0	3	1	5	1	4	1	3	0	1
65	2	1	0	1	0	1	0	2	0	1	0	1	0	1
66	1	1	0	1	0	1	0	2	0	2	0	2	0	1
67	2	4	1	4	0	4	0	5	1	4	0	4	0	1
68	1	7	4	5	0	6	4	8	4	7	3	7	3	1
69	2	4	1	4	0	3	1	5	1	4	0	3	0	1
70	1	3	0	3	0	3	0	3	0	3	0	3	0	1
71	2	2	0	2	0	2	0	3	0	2	0	2	0	1
72	1	2	0	2	0	1	0	3	0	2	0	2	0	1

73	2	3	0	3	0	3	0	4	0	3	0	2	0	1
74	2	4	0	4	0	3	0	4	1	3	0	3	0	1
75	1	5	1	5	0	5	0	7	2	7	1	6	1	3
76	1	3	0	3	0	2	0	5	1	5	1	4	1	1